A reference work of monitoring recommendations for the 30 chronic conditions tracked by the CMS Chronic Conditions Data Warehouse (CCW). One monograph per condition. Every recommendation is footnoted back to the originating association and source document so the content can be updated as guidelines evolve.
This is a practice planning and education resource for administrators, physicians, and providers. It does not replace clinical judgment, define the totality of service for any patient, or generate patient-specific recommendations.
cmid/
├── README.md this file
├── index.md table of contents — conditions by prevalence and by category
├── bibliography.md master list of cited associations + source documents with URLs
├── conditions/
│ ├── _template.md the template every condition file follows
│ ├── 01-hypertension.md
│ ├── 02-hyperlipidemia.md
│ └── ... (30 files, numbered by 2022 CCW prevalence rank)
├── render.py build script — produces out/cmid.html
└── out/
└── cmid.html rendered single-file reference; the artifact for sharing
When multiple associations issue overlapping recommendations, the synthesized recommendation follows this authority order:
Conflicts are flagged, never silently resolved — the disagreement itself is often the signal a clinician needs. When sources agree on an item but disagree on interval, the more conservative (more frequent) interval wins.
Recommendations change. To update:
conditions/NN-name.md file.bibliography.md.python render.py to regenerate out/cmid.html.Markdown is the source of truth. HTML is the artifact.
pip install markdown
python render.py
Open out/cmid.html in any browser.
CMS CCW 30 chronic conditions, 2022 Medicare FFS prevalence (n ≈ 28.6M beneficiaries). Source: CCW Table B.2.a, April 2024.
Click any condition to open its full monograph (prose, footnoted recommendations, source citations).
Compact monitoring schedule across all 30 conditions. Item-type prefixes inside each cell: L lab · I imaging · P physical exam · S functional/survey. Population qualifiers and source citations live in the individual condition pages.
| # | Condition | Cat. | ICD-10 | 2022 | Every visit | Quarterly | 6 mo | Annually | 2–3 yr | As indicated |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Hypertension | CV/Met | I10–I15 | 66.8% | P: BP, wt/BMI, cardiac ausc. | — | L: BMP, K+, eGFR* | L: lipid, UACR, glucose · P: fundoscopic · S: PHQ-9, ASCVD risk | P: ABI (if ≥65/smoker) | L: TSH · I: ECG, Echo, Renal US |
| 2 | Hyperlipidemia | Met | E78 | 65.5% | P: BP, wt/BMI · S: adherence, lifestyle | L: lipid panel (during titration) | — | L: lipid panel (stable), HbA1c | S: ASCVD risk (PREVENT, q4–6 yr) | L: Lp(a) once, apoB, ALT/CK baseline · I: CAC score |
| 3 | RA / OA | MSK | M05–M06, M15–M19 | 36.2% | RA: P: TJC/SJC · S: disease activity (DAS28/RAPID3), HAQ. OA: P: joint exam, BMI · S: pain (NRS/VAS), function (WOMAC/KOOS/HOOS) | RA: L: DMARD safety labs · S: disease activity to target | RA: S: disease activity in remission | RA: I: hand/foot radiographs · L: vaccinations, TB · S: HCQ retinopathy screen (≥5 yr) | — | RA: L: TB/HBV/HCV pre-biologic, HBV DNA. OA: L: NSAID/acetaminophen safety · I: radiographs (Dx or surgical workup) |
| 4 | BPH (M) | Other | N40 | 29.1% | S: IPSS at each visit | — | — | P: DRE · S: IPSS annual, 5-ARI response | — | L: UA, PSA (per shared decision; pre–5-ARI; 6 mo after start), Cr (red flags) · S: PVR, uroflow, 4–12 wk response visit, post-op 1/3/6/12 mo |
| 5 | Diabetes | Met | E11 | 26.4% | P: BP, wt/BMI, hypoglyc review · L: CGM TIR · S: smoking | L: HbA1c (if not at goal) | L: HbA1c (at goal), 4–12 wk lipid post-statin | L: UACR, lipid, ALT/FIB-4, TSH, eGFR · P: foot, dilated eye, neuropathy, dental · S: ASCVD, PHQ-9, distress, GAD-7, vaccines, DSMES | — | L: B12, K+, CKD-tier labs · I: DEXA · S: MNT, post-bariatric malnutrition |
| 6 | Cataract | Ophth | H25–H26 | 26.4% | — | — | — | P: comprehensive eye exam (≥65); annual if diabetic · S: BCVA, IOP, slit-lamp | P: comprehensive eye exam (age 55–64) | I: optical biometry (pre-op) · P: post-op day 1, week 1–2, month 1 · S: functional impairment (VF-14) for surgical referral |
| 7 | Ischemic Heart Disease | CV | I20–I25 | 21.8% | P: BP, wt/BMI, physical activity · S: adherence, tobacco | L: lipid panel during titration | — | L: lipid panel (stable), HbA1c (if DM), flu/COVID vaccination | S: PHQ-2/PHQ-9, ASCVD risk | I: stress imaging / echo / CTA only with symptom change (routine = Class 3) · S: cardiac rehab referral post-MI/PCI/CABG (36 sessions, CMS) |
| 8 | Anemia | Met | D50–D53, D63 | 21.7% | S: symptom assessment during active treatment | L: CBC + iron studies on ESA (CKD); CBC q3 mo on oral iron (1st yr) | L: Hgb screening (CKD G4–G5) | L: Hgb screening (CKD G3); CBC after iron repletion | L: CBC q5–10 yr in women of childbearing age (CDC) | L: workup CBC+retic+ferritin+B12+folate+eGFR; Hgb q2–4 wk on ESA; CBC 1 mo on oral iron; B12 replacement labs (retic 1 wk, MMA 1 wk–3 mo, CBC 8 wk); GI eval for adult IDA in men / postmenopausal women |
| 9 | Hypothyroidism | Met | E03 | 21.3% | P: weight, HR, BP (titration); annual when stable · S: symptom assessment | — | L: TSH q6–12 mo (subclinical observed); TSH 6 mo post-stabilization | L: TSH (stable on LT4); lipid panel (untreated subclinical) | — | L: TSH q4–8 wk (titration); free T4 (adjustment / pregnancy / central); TPO Ab once; TSH q4 wk to 20 wk + once 26–32 wk (pregnancy); confirmatory TSH at 2–3 mo |
| 10 | Depression / Mood | MH | F31–F34 | 19.7% | S: adherence, AE review, C-SSRS suicide risk during active tx · P: weight / BP (SGA users) | S: PHQ-9 monthly (acute) / q2–4 wk (continuation) · L: lithium / VPA / CBZ levels (stable) | L: lithium Cr + TSH; CBC + LFTs (VPA / CBZ stable) · S: AIMS q6 mo (SGA) | L: BP + glucose + lipids annually (SGA stable) · S: PHQ-2 / PHQ-9 screening per USPSTF | — | L: lithium twice weekly on initiation; CBZ CBC + LFTs q2–4 wk first 2 mo; weight on SGA 4 / 8 / 12 wk · S: MDQ at workup (bipolar), CoCM / BHI registry |
| 11 | CKD | Renal | N18–N19 | 18.7% | P: standardized BP (target SBP <120) · L: BMP on RAAS / SGLT2i / eGFR <30 · S: med reconciliation, lifestyle | L: Cr/eGFR + UACR (G4 ~3×/yr, G3bA3); Ca/PO4/PTH (G4 q3–6 mo, G5 q1–3 mo) | L: Cr/eGFR + UACR (G3 A2–A3); Hgb (G4–G5); Ca/PO4/PTH (G3a–G3b) | L: Cr/eGFR + UACR (G1–G3a A1); Hgb (G3); HbA1c ≥2×/yr (DM); vaccination · S: KFRE | — | L: cystatin C, lipid panel once, K+Cr at 2–4 wk post RAAS/SGLT2i/MRA · S: nephrology referral (KFRE thresholds, refractory complications) |
| 12 | Glaucoma | Ophth | H40 | 15.0% | P: tonometry (IOP), drop adherence | P: comprehensive eye exam (q1–3 mo if progressing) | I: OCT q6–12 mo · S: visual field q6–12 mo · P: comprehensive eye exam (q3–6 mo recently controlled) | P: comprehensive eye exam (q6–12 mo if stable); gonioscopy q1–5 yr | — | P: pachymetry baseline · I: stereo disc photos; post-LPI / post-surgical follow-up · S: target IOP setting (20–30% below baseline) |
| 13 | Atrial Fibrillation | CV | I48 | 14.1% | P: BP/HR/rhythm, weight · S: symptoms, activity, alcohol, tobacco · I: ECG if symptom change | L: INR (warfarin monthly); BMP/Cr/hepatic on DOAC at low CrCl/age ≥75 | — | L: Cr/eGFR (DOAC), HbA1c, lipid, CBC · S: CHA2DS2-VASc, HAS-BLED, OSA screen | — | I: TTE at Dx + clinical change / pre-procedure; TEE pre-cardioversion / ablation / LAAO · S: LAAO candidacy, weight-loss program BMI ≥27 |
| 14 | COPD | Resp | J44 | 12.8% | P: SpO2, smoking, BMI · S: CAT, mMRC, exacerbation history | — | — | L: spirometry · S: vaccinations, PR review | — | L: AAT once, eosinophil count, ABG (SpO2 ≤92%) · I: chest CT (red flags / lung-cancer screen) · S: 6MWT, LTOT assessment, PR within 3 wk of exacerbation discharge |
| 15 | Heart Failure | CV | I50 | 12.3% | P: BP/HR/weight/volume status · S: NYHA, weight diary | L: BMP 1–2 wk after GDMT start / titration; q3–6 mo stable · S: KCCQ q3–6 mo | L: BMP stable q3–6 mo | L: iron studies (HFrEF), lipid, HbA1c, TSH, CBC · S: PHQ-9, cardiac-rehab review | — | L: initial workup at Dx; BNP/NT-proBNP at presentation + admission + predischarge · I: TTE at Dx + clinical change / 3–6 mo post-GDMT for HFimpEF · S: CR referral (LVEF ≤35% NYHA II–IV), CardioMEMS for NYHA III |
| 16 | Osteoporosis | MSK | M80–M81 | 11.5% | — | L: serum Ca prior to IV zoledronate / denosumab | S: denosumab continuity (no gap >7 mo) | P: standing height, fall-risk screen · L: 25-OH vit D, calcium intake · S: FRAX recalc | I: central DXA q2 yr (screening; on therapy q1–2 yr AACE / 1–3 yr Endo) | L: secondary-causes workup, CTX / P1NP · I: VFA (height loss / glucocorticoids / T ≤ −2.5) · S: drug-holiday reassessment, anabolic-to-antiresorptive sequencing |
| 17 | Prostate Cancer (M) | Cancer | C61 | 9.9% | S: distress, hot flashes / mood / sexual (ADT) · P: BP on ADT | L: PSA on AS, testosterone + PSA on ADT, abiraterone LFTs/K+/BP | L: PSA post-curative (q6–12 mo first 5 yr) | L: PSA post-curative (annual after 5 yr), lipid + glucose (ADT), Ca / vit D · P: DRE on AS · S: urinary continence, sexual function, age-appropriate Ca screening | I: DEXA on ADT (baseline + q1–2 yr); mpMRI on AS (q1–3 yr) | I: confirmatory biopsy on AS (6–12 mo then q2–5 yr); CT + bone scan / PSMA PET at BCR / progression; imaging in mCRPC q6–12 mo |
| 18 | Non-Alzheimer's Dementia | Neuro | F01–F02, G31 | 8.7% | P: Beers Criteria med review, antipsychotic appropriateness · S: NPI-Q, vascular risk-factor control | — | S: caregiver burden (Zarit) | L: TSH, B12 at Dx · P: fall-risk, driving safety · S: MoCA / Mini-Cog, ADL / IADL, FAST / CDR staging, depression, ACP, CMS CPT 99483 | — | I: MRI / CT once at Dx · S: GUIDE Model enrollment, HRSN screening |
| 19 | Breast Cancer (F) | Cancer | C50 | 8.2% | P: lymphedema, neuropathy / AI arthralgia · S: distress, fatigue, vasomotor, sexual / vaginal, cognitive | L: LFTs / cardiotoxicity (chemo); I: echo q3 mo on trastuzumab | P: H&P q3–6 mo (yr 1–3); I: echo q6 mo × 2 yr post-trastuzumab | I: annual mammography · L: lipid + Ca/vit D (AI) · P: annual gyn (tamoxifen) · S: lifestyle, second-primary screening | I: DEXA q2 yr (on AI; tamoxifen + GnRH) | I: breast MRI annually if high-risk only; routine surveillance CT / bone / PET / markers NOT recommended |
| 20 | Asthma | Resp | J45 | 7.4% | P: inhaler technique · S: ACT / ACQ, adherence, triggers, smoking, asthma action plan, exacerbation history | — | — | P: spirometry (q1–2 yr) · S: comorbidities (rhinitis / OSA / GERD / VCD / mood), vaccinations | — | L: FeNO, eosinophil count, IgE (severe / biologic workup) · P: PEF home monitoring (moderate-severe) · S: step-up / step-down, biologic candidacy, pulmonary rehab, SCIT (mild-moderate allergic only) |
| 21 | Stroke / TIA | Neuro | I61, I63, G45 | 7.0% | P: BP (target <130/80), weight · S: antithrombotic adherence, tobacco, alcohol, activity, fall risk | L: INR monthly (warfarin), lipid during titration | L: lipid (stable) | L: HbA1c (DM), CBC / LFTs / Cr (DOAC) · I: baseline ECG · S: PHQ-9, MoCA, influenza vaccine | — | I: ≥30 day cardiac monitoring post-cryptogenic; carotid imaging post-CEA / CAS; brain CT / MRI for new symptoms · S: DAPT 21–90 days (minor stroke / high-risk TIA), PT / OT / SLP rehab, OSA evaluation, dysphagia screen, mRS at 90 days |
| 22 | Alzheimer's | Neuro | G30 | 2.5% | P: Beers / antipsychotic review · S: NPI-Q, vascular RF, ChEI / memantine efficacy | — | S: caregiver burden (Zarit) | L: TSH / B12 at Dx · P: fall-risk (TUG), driving / home safety · S: MoCA / Mini-Cog, ADL / IADL, FAST / CDR, GDS-15, ACP, CMS CPT 99483, exercise Rx | — | L: APOE + amyloid PET / CSF before anti-amyloid · I: MRI at Dx; ARIA surveillance MRI per lecanemab / donanemab schedule · S: CMS Monoclonal Antibody Registry, GUIDE enrollment |
| 23 | Parkinson's | Neuro | G20 | 1.9% | P: MDS-UPDRS I–IV, H&Y, orthostatic BP, dopaminergic-regimen + dopamine-blocker review · S: psychosis, QUIP-RS (DA), falls, ACP, exercise | — | L: DBS programming / battery / neuropsych (DBS) · P: dental / oral | P: TUG / pull test, orthostatic BP, driving · S: PD Dx review (MDS criteria), MoCA, PHQ-9 / GDS, RBDSQ / ESS, SCOPA-AUT, EAT-10, speech, GI, vaccinations, Beers | — | L: PD GENEration genetic testing · I: MRI (atypical), PSG (RBD) · S: PT / OT / SLP, pimavanserin / clozapine / quetiapine for PD psychosis |
| 24 | Colorectal Cancer | Cancer | C18–C20 | 1.5% | — | L: CEA q3–6 mo × 2 yr (stage II / III) · P: H&P q3–6 mo × 2 yr | L: CEA q6 mo through yr 5 · I: CT C / A / P q6–12 mo × 5 yr (stage II–IV); MRI pelvis q6 mo × 3 yr (rectal / watch-and-wait); proctoscopy q3–6 mo · P: H&P q6 mo through yr 5 · S: distress / PHQ-9 | I: CT C / A / P annually × 5 yr (ACS alt); colonoscopy at 1 yr → 3 yr → q5 yr · P: H&P, ostomy, CIPN · S: lifestyle, 2nd-cancer screen, Lynch surveillance | — | S: fatigue, sexual fx, fertility, LARS, WOC ostomy, duloxetine for CIPN, survivorship care plan |
| 25 | Acute MI | CV | I21–I22 | 1.3% | P: BP, weight / BMI, physical activity · S: DAPT / BB / ACEi / SGLT2i / MRA / GLP-1 RA / statin adherence, tobacco, Mediterranean / DASH | L: lipid 4–8 wk post-statin, then q3–12 mo · S: clinical f/u q4–6 mo yr 1 | — | L: lipid (LDL <70 / <55), HbA1c, flu / COVID / RSV · S: PHQ-2 / PHQ-9, alcohol, activity counseling | — | I: echo for LVEF ~40 d post-MI (ICD decision) · S: cardiac rehab pre-discharge (CMS NCD 20.10, 36 sessions); ICD ≥40 d post-MI / ≥90 d post-revasc if LVEF ≤35% |
| 26 | Pneumonia | Resp | J12–J18 | 1.3% | S: smoking cessation | — | — | L: pneumococcal (PCV20 / 21 once ≥50), flu, RSV ≥75, COVID, Tdap · P: BMI, COPD optimization · S: vaccine review, post-CAP cognitive surveillance (older adults) | — | L: blood cultures / sputum / Legionella + Pneumo Ag (severe CAP); procalcitonin (de-escalation only); recurrent-pneumonia workup (Ig, HIV) · I: 6–8 wk CXR (persistent sx / smokers ≥50 / recurrent same lobe); chest CT (structural) · P: SpO2 / ABG, swallow eval, delirium screen · S: 1–2 wk post-CAP visit |
| 27 | Lung Cancer | Cancer | C34 | 1.3% | P: dyspnea / cough · S: smoking cessation, distress | L: irAE labs (TSH / LFT / glucose / cortisol) pre-IO; response imaging q6–12 wk on systemic Rx | I: chest CT q6 mo × 2–3 yr (stage I–II NSCLC); q6 mo × 3 yr (stage III); brain MRI q3–4 mo yr 1 then q6 mo yr 2 (LS-SCLC) · P: H&P q6 mo × 2–3 yr | L: broad molecular profiling at Dx (advanced nonsquamous NSCLC) · I: annual LDCT after initial window; LDCT screening 50–80 / 20+ pack-yr (USPSTF B; CMS 50–77, G0296) · P: H&P · S: fatigue, PHQ-9 / GAD-7, CIPN, diet, 2nd-cancer screen, vaccinations | — | P: dental pre-thoracic RT / on bone-modifying agents · S: pulmonary rehab pre / post-resection |
| 28 | Hip / Pelvic Fx | MSK | S72, S32, M84 | 1.2% | P: pain, mobility / PT / OT · S: Beers fall-risk-med review | P: rehab — IRF ≥3 hr / day, SNF PT / OT ≥5 d / wk | S: denosumab continuity (no gap >7 mo) | L: 25-OH vit D, Ca intake · I: DEXA q1–2 yr on therapy · P: standing height, TUG, CDC STEADI · S: FRAX recalc, PHQ-2 / PHQ-9 at 1 / 3 / 6 / 12 mo PCP visits | — | L: secondary-causes workup, Ca pre-IV zoledronate / denosumab, CTX / P1NP · I: baseline DEXA, VFA · P: comprehensive geriatric assessment, CAM delirium screen · S: FLS / Own the Bone, prompt anti-resorptive (zoledronic acid / oral BP / denosumab), VTE prophylaxis 10–35 d |
| 29 | Endometrial Cancer (F) | Cancer | C54 | 1.1% | S: recurrence-symptom education, distress | L: CA-125 only if elevated at baseline · P: H&P + pelvic exam q3–6 mo × 2–3 yr (stage III / IV or serous / clear cell q3 mo) | P: H&P + pelvic exam q6 mo through yr 5 · I: CT C / A / P q6 mo × 3 yr (stage III–IV, serous / clear cell, carcinosarcoma) | P: H&P, lymphedema surveillance · S: lifestyle, CV risk, vasomotor / sexual / vaginal health, bone health (DXA), age-appropriate cancer screening | — | L: universal MMR IHC ± MSI at Dx (Lynch); germline if MMR-d; irAE labs on ICI · I: vaginal / pelvic MRI for sx; response imaging q9–12 wk on systemic Rx · S: vaginal cuff Pap NOT recommended (symptom-driven only) |
| 30 | Urologic Cancer | Cancer | C64–C67 | 0.9% | — | L: urine cytology q3–6 mo × 2 yr (int / high-risk NMIBC); BCG response cytology 3 + 6 mo · I: cystoscopy q3–4 mo × 2 yr (high-risk NMIBC), q3–6 mo (int-risk); CT C / A / P q6–12 mo × 2–3 yr post-cystectomy MIBC; abd CT / MRI + chest CT q3–6 mo × 3 yr (RCC stage II–III); response imaging q6–16 wk on systemic | L: renal fx + upper-tract imaging q6 mo through yr 3 (post-cystectomy); BMP / acid-base · I: cystoscopy q6 mo yrs 3–4 (NMIBC) | L: renal fx + upper-tract imaging after yr 3; annual B12 (ileal diversion) · I: cystoscopy annually after yr 4–5 (NMIBC); upper-tract imaging q1–2 yr (int / high-risk NMIBC); abd imaging × 3 yr + chest CT annually × 5 yr (stage I RCC) · P: H&P annually | I: shared decision to d/c cystoscopy after 5 yr recurrence-free (low-risk NMIBC) | L: urinary biomarkers (not replace cystoscopy), irAE labs on ICI / TKI · I: urethral wash cytology if urethra retained; routine bladder screening NOT recommended (USPSTF I) · S: renal-function preservation counseling, active-surveillance reassessment (small renal mass) |
* every 6 months on RAAS therapy (ACE/ARB/MRA) or diuretic; annually otherwise. See each condition's monograph for full population qualifiers and source citations.
Cardiovascular — Hypertension · Ischemic Heart Disease · Atrial Fibrillation · Heart Failure · Acute MI Metabolic — Hyperlipidemia · Diabetes · Anemia · Hypothyroidism Renal — Chronic Kidney Disease Respiratory — COPD · Asthma · Pneumonia Neurologic — Non-Alzheimer's Dementia · Stroke / TIA · Alzheimer's Disease · Parkinson's Disease Musculoskeletal — Rheumatoid Arthritis / Osteoarthritis · Osteoporosis · Hip / Pelvic Fracture Mental Health — Depression / Bipolar / Mood Disorders Ophthalmic — Cataract · Glaucoma Cancer — Prostate (M) · Breast (F) · Colorectal · Lung · Endometrial (F) · Urologic Other — Benign Prostatic Hyperplasia (M)
ICD-10: I10 (essential), I11–I15 (secondary/complicated forms) CCW prevalence (2022 Medicare FFS): 66.8% — rank 1 of 30 Category: Metabolic / Cardiovascular Primary associations consulted: ACC/AHA, USPSTF, NHLBI, CMS, CDC
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | BMP, K+, eGFR* | Lipid panel, UACR, fasting glucose / HbA1c | — | TSH |
| Imaging | — | — | — | — | — | ECG (baseline), Echo (Stage 2 or LVH), Renal US (resistant HTN) |
| Physical exam | BP, weight / BMI, cardiac auscultation | — | — | Fundoscopic exam | ABI / peripheral pulse (if ≥65 or smoker) | — |
| Functional / surveys | — | — | — | PHQ-9, 10-yr ASCVD risk (Pooled Cohort Equations) | — | — |
* every 6 months if on ACE/ARB, diuretic, or MRA; otherwise annually.
Adults with diagnosed hypertension should have blood pressure measured at every clinical encounter, supplemented by out-of-office measurement (home BP monitoring or 24-hour ambulatory BP monitoring) at diagnosis and when treatment changes.12 The current ACC/AHA target is <130/80 mmHg for most adults.1 Baseline laboratory evaluation screens for secondary causes and end-organ damage; routine surveillance focuses on renal function and electrolytes (especially in patients on RAAS-acting agents or diuretics), lipid status, glycemic status, and urinary albumin. Annual reassessment of 10-year ASCVD risk informs concurrent statin and aspirin decisions.1 Echocardiography is reserved for new Stage 2 hypertension, suspected left ventricular hypertrophy, or clinical change. The most conservative interval among overlapping recommendations wins when sources disagree on cadence.
Whelton PK et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115. See bibliography.md → aha-htn-2017. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
US Preventive Services Task Force. Screening for Hypertension in Adults: Reaffirmation Recommendation Statement. JAMA. 2021;325(16):1650-1656. See bibliography.md → uspstf-htn-2021. ↩↩↩↩
ICD-10: E78.5 (unspecified), E78.0 (pure hypercholesterolemia), E78.1 (hypertriglyceridemia), E78.2 (mixed) CCW prevalence (2022 Medicare FFS): 65.5% — rank 2 of 30 Category: Metabolic Primary associations consulted: ACC/AHA, USPSTF, NLA, AACE, NHLBI
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Lipid panel during titration (4–12 wk after start or change) | — | Lipid panel (stable patient), HbA1c (statin-associated DM surveillance) | — | Lp(a) once in adulthood, apoB (residual-risk question), ALT baseline (pre-statin), CK baseline (high SAMS risk only) |
| Imaging | — | — | — | — | — | Coronary artery calcium (CAC) score — borderline/intermediate risk where statin decision is uncertain |
| Physical exam | BP, weight / BMI, smoking status | — | — | — | — | — |
| Functional / surveys | Adherence review, diet / lifestyle counseling | — | — | — | ASCVD 10-year risk recalculation (every 4–6 years via PREVENT equations) | — |
Adults with diagnosed hyperlipidemia should have a follow-up lipid panel 4–12 weeks after starting or changing lipid-lowering therapy to confirm adherence and percent LDL-C reduction (≥50% on high-intensity statin, ≥30% on moderate-intensity), then every 3–12 months until stable, transitioning to annual surveillance once at goal on unchanged therapy.14 The 2026 ACC/AHA Dyslipidemia Guideline reintroduced explicit numeric LDL-C targets — <55 mg/dL for very-high-risk ASCVD, <70 mg/dL for high risk, <100 mg/dL for borderline/intermediate — and added one-time universal Lp(a) measurement as a Class I recommendation.2 Intensification (ezetimibe, then PCSK9 inhibitor, bempedoic acid, or inclisiran) is triggered when LDL-C remains above the risk-stratified threshold despite maximally tolerated statin. Routine ALT and CK surveillance is not recommended; check ALT once before statin initiation and CK only at baseline in patients at increased SAMS risk, then symptom-driven thereafter.1 Each visit should include adherence review, lifestyle counseling, BP/BMI/smoking assessment, and periodic recalculation of 10-year ASCVD risk using the AHA PREVENT equations.
Grundy SM et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. See bibliography.md → accaha-chol-2018. ↩↩↩↩↩↩↩↩↩↩↩↩↩
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026. See bibliography.md → accaha-dyslip-2026. ↩↩↩↩↩↩↩↩↩
USPSTF. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement. JAMA. 2022;328(8):746-753. See bibliography.md → uspstf-statin-2022. ↩↩
Jacobson TA et al. NLA Recommendations for Patient-Centered Management of Dyslipidemia. J Clin Lipidol. 2015. See bibliography.md → nla-2015. ↩↩↩↩
Jellinger PS et al. AACE/ACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract. 2017. See bibliography.md → aace-2017. ↩
AACE Task Force. Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocr Pract. 2025. See bibliography.md → aace-2025. ↩
ICD-10: RA — M05.x, M06.x. OA — M15–M19. CCW prevalence (2022 Medicare FFS): 36.2% — rank 3 of 30 (combined; CCW does not separate) Category: Musculoskeletal Primary associations consulted: ACR, EULAR, USPSTF (limited), NIAMS, Arthritis Foundation, AAO (HCQ retinopathy)
RA and OA are distinct diseases combined into a single CCW category. They share little in monitoring approach and are addressed separately below.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | CBC, ALT/AST, Cr (DMARD safety after stable); lipid panel + CBC at 4–8 wk then q3–6 mo on tocilizumab / sarilumab / JAK | — | TB screening (if ongoing exposure risk); vaccination status review (influenza, pneumococcal, RZV, COVID-19) | — | TB / HBV / HCV pre-biologic; HBV DNA q1–3 mo if HBcAb+ on biologic without prophylaxis; baseline labs pre-DMARD initiation |
| Imaging | — | — | — | Hand / wrist / foot radiographs (every 1–2 years to track erosive progression) | — | — |
| Physical exam | 28-joint tender / swollen joint count | — | — | — | — | — |
| Functional / surveys | Disease activity (DAS28-CRP, CDAI, SDAI, RAPID3, or PAS-II); HAQ-DI or MDHAQ | Disease activity every 3 mo until target reached | Disease activity every 6 mo in sustained remission | Dilated fundus + visual fields + SD-OCT (HCQ users starting year 5; sooner with risk factors) | — | — |
Primary-care monitoring of RA follows a treat-to-target framework: at every visit (minimum every 3 months until low disease activity or remission, every 6 months thereafter), document a validated composite disease-activity score (DAS28-CRP, CDAI, SDAI, RAPID3, or PAS-II), a 28-joint count, and a functional assessment (HAQ-DI or MDHAQ).12 DMARD-safety labs (CBC, ALT/AST, creatinine) are obtained at baseline and every 2–4 weeks during the first 3 months of methotrexate, leflunomide, or sulfasalazine, every 8–12 weeks during months 3–6, then every 12 weeks; hydroxychloroquine requires only baseline labs but mandates annual ophthalmologic screening with visual fields and SD-OCT starting at 5 years of use (sooner with risk factors), with the dose capped at ≤5 mg/kg actual body weight.26 Biologics and JAK inhibitors require pre-treatment TB, HBV, and HCV screening; tocilizumab, sarilumab, and JAK inhibitors add lipid surveillance at 4–8 weeks and then every 3–6 months.2 Hand and foot radiographs at baseline and periodically (every 1–2 years) track erosive progression; vaccinations are reviewed annually.4
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | — | — | ALT (chronic acetaminophen); CBC / Cr / BP (chronic NSAID periodic surveillance) |
| Imaging | — | — | — | — | — | Plain radiographs — diagnostic uncertainty or surgical planning; not recommended for routine surveillance |
| Physical exam | Joint exam (ROM, effusion, alignment, crepitus); BMI / weight in overweight knee or hip OA | — | — | — | — | — |
| Functional / surveys | Pain (NRS / VAS); function (WOMAC or KOOS knee; HOOS hip; AUSCAN / FIHOA hand); exercise / self-management adherence | — | — | — | — | Depression / anxiety / sleep / coping screen |
OA surveillance is symptom- and function-driven, not test-driven. At each visit reassess pain (NRS or VAS) and function using a validated instrument (WOMAC or KOOS for knee, HOOS for hip, AUSCAN or FIHOA for hand), confirm engagement in the strongly recommended exercise and self-management program, and (in knee or hip OA) measure BMI to track the clinically meaningful 5% weight-loss target.5 Hepatotoxicity surveillance with ALT is advised for chronic acetaminophen users, particularly at doses approaching 3 g/day; CBC, creatinine, and blood pressure should be checked periodically in chronic oral NSAID users.5 The 2019 ACR/AF guideline does not recommend routine surveillance imaging — radiographs are reserved for diagnostic uncertainty or to evaluate worsening symptoms and surgical candidacy. Mental health, sleep, and coping should be screened given their high comorbid burden and direct effect on pain perception.5
Fraenkel L et al. 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. See bibliography.md → acr-ra-2021. ↩↩↩↩↩↩↩
Singh JA et al. 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68(1):1-25. See bibliography.md → acr-ra-2015. ↩↩↩↩↩↩↩↩↩↩↩
England BR et al. 2022 ACR Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for RA. Arthritis Care Res. 2023. See bibliography.md → acr-ra-2022-integ. ↩
Bass AR et al. 2022 ACR Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res. 2023. See bibliography.md → acr-vax-2022. ↩↩
Kolasinski SL et al. 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233. See bibliography.md → acr-oa-2019. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Marmor MF et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. See bibliography.md → aao-hcq-2016. ↩↩↩
NIAMS. Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take. See bibliography.md → niams-ra. ↩
ICD-10: N40.0, N40.1, N40.2, N40.3 CCW prevalence (2022 Medicare FFS): 29.1% (males only) — rank 4 of 30 Category: Other (urologic; males only) Primary associations consulted: AUA, USPSTF (PSA screening only), NIDDK, AAFP, Urology Care Foundation
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | — | — | Urinalysis (baseline; repeat with new hematuria / UTI / worsening symptoms); PSA (baseline if would change management, pre–5-ARI, per shared decision for PCa screening — USPSTF every 2–4 yr if 55–69); PSA reassessment 6 mo after starting 5-ARI; serum creatinine (red-flag features only) |
| Imaging | — | — | — | — | — | — |
| Physical exam | — | — | — | DRE (NIDDK: annually or more often; AUA: baseline + clinical-judgment thereafter) | — | — |
| Functional / surveys | IPSS (AUA-SI) at each follow-up visit | — | — | IPSS annual reassessment (watchful waiting); 5-ARI response at 3–6 months | — | Post-void residual (PVR — retention or pre-surgical); uroflowmetry (pre-procedure or discordant symptoms); 4–12 wk response visit after starting alpha-blocker / PDE5i / beta-3 agonist / anticholinergic; post-procedural follow-up at 1, 3, 6, 12 months |
For a male with diagnosed BPH/LUTS, surveillance is built around the IPSS administered at baseline and at every follow-up; mild or non-bothersome symptoms (IPSS ≤7) are managed by watchful waiting with annual reassessment including symptom score, focused history, urinalysis as indicated, and DRE.134 Patients started on an alpha-blocker, PDE5 inhibitor, beta-3 agonist, or anticholinergic should be reassessed at 4–12 weeks (typically ≈4 weeks) for response and tolerability; those on a 5-ARI are reassessed at 3–6 months, with a new PSA baseline established at ~6 months and measured PSA doubled thereafter for cancer-risk interpretation.1 Worsening IPSS, elevated or rising PVR, recurrent UTI, hematuria, retention, renal impairment, or stones trigger urology referral. PSA in the BPH-monitored patient serves two distinct purposes that must not be conflated: a BPH-management role (estimates prostate volume; cutoff >1.5 ng/mL guides 5-ARI candidacy) and a prostate-cancer screening role (USPSTF restricts to shared decision-making in men 55–69 every 2–4 years; recommends against in men ≥70).12
No routine imaging is recommended for surveillance.1
Sandhu JS et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. See bibliography.md → aua-bph-2023. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
USPSTF. Final Recommendation Statement: Prostate Cancer Screening (2018). See bibliography.md → uspstf-pca-2018. ↩↩↩
NIDDK. Enlarged Prostate (Benign Prostatic Hyperplasia). See bibliography.md → niddk-bph. ↩↩↩
Ng M, Leslie SW, Baradhi KM. Benign Prostatic Hyperplasia: Rapid Evidence Review. Am Fam Physician. 2023;107(6):613-622. See bibliography.md → aafp-bph-2023. ↩↩↩↩↩
ICD-10: E11.x (Type 2 Diabetes Mellitus, with or without complications) CCW prevalence (2022 Medicare FFS): 26.4% — rank 5 of 30 Category: Metabolic Primary associations consulted: ADA, AACE, USPSTF, KDIGO, AGS, CMS, NIDDK
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | CGM Time-in-Range review (if applicable) | HbA1c (if not at goal or after therapy change) | HbA1c (stable, at goal); Cr / eGFR (CKD G3); 4–12 wk lipid panel post statin start / change | UACR, Cr / eGFR (no CKD), lipid panel (on statin), ALT / AST + FIB-4 (MASLD screen), TSH (periodic) | — | B12 (long-term metformin); K+ (on ACEi / ARB / MRA / finerenone); risk-tier CKD labs (G3 q6–12 mo, G4 q3–5 mo, G5 q1–3 mo) |
| Imaging | — | — | — | — | — | DEXA bone density (≥5 yr post-diagnosis; q2–3 yr per fracture risk; SGLT2i / TZD users) |
| Physical exam | BP, weight / BMI / waist, hypoglycemia review | — | — | Comprehensive foot exam, dilated eye exam (q1–2 yr if no retinopathy and at glycemic goal; annual if retinopathy), distal polyneuropathy assessment (10-g monofilament + pinprick / temperature / vibration), dental exam | — | Foot exam every visit if prior ulcer / sensory loss |
| Functional / surveys | Smoking / tobacco / e-cigarette + cessation counseling | — | — | ASCVD 10-yr risk (PREVENT), PHQ-2 / PHQ-9, GAD-7, diabetes distress (DDS or PAID), disordered eating screen, SDoH screen, vaccination review, DSMES reinforcement; cognitive screen + function / falls / frailty (≥65); malnutrition screen (weight-loss pharmacotherapy or post-metabolic surgery) | — | MNT (Medicare NCD 180.1: initial 3 hr + 2 hr / yr); DSMES at diagnosis, annually, with new complications, at care transitions (Medicare DSMT: 10 hr initial + 2 hr / yr) |
Primary-care monitoring of an adult with Type 2 Diabetes is built around visits every 3–6 months — quarterly when not at glycemic goal or after a therapy change, every 6 months when stable and at goal.1 At every visit document weight / BMI, blood pressure (target <130/80; consider <120 systolic in high CV / kidney risk), hypoglycemia events, medication adherence and tolerability, tobacco use, and (when on CGM) time-in-range (target >70%).1 The annual lab panel includes HbA1c (twice yearly minimum; target <7% for most nonpregnant adults), UACR, serum creatinine / eGFR, lipid panel (annually once on a statin), ALT / AST with FIB-4 for MASLD, and TSH periodically; B12 is checked periodically on long-term metformin and potassium when on ACEi / ARB / MRA / finerenone.12 Complications surveillance comprises annual comprehensive foot exam (every visit if prior ulcer or sensory loss), distal polyneuropathy assessment, dilated eye exam at diagnosis and every 1–2 years thereafter if low risk, and CKD risk-tier-driven kidney monitoring (1–4× yearly).1 Cardiovascular surveillance includes annual ASCVD risk estimation (PREVENT), lipid optimization (LDL <70 primary prevention, <55 with ASCVD), and BP control. Psychosocial and geriatric surveillance — at least annual depression, diabetes distress, anxiety, disordered eating, SDoH, and (≥65) cognitive and function / fall-risk screening — round out the visit. Immunizations are reviewed annually; DSMES and MNT are reinforced at diagnosis, yearly, with new complications, or at care transitions.
American Diabetes Association. Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl. 1). See bibliography.md → ada-soc-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
KDIGO. 2022 Clinical Practice Guideline for Diabetes Management in CKD. Kidney Int. 2022. See bibliography.md → kdigo-dm-2022. ↩↩↩↩
USPSTF. Screening for Prediabetes and Type 2 Diabetes: Recommendation Statement. JAMA. 2021;326(8):736-743. See bibliography.md → uspstf-dm-2021. ↩
Samson SL et al. AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm — 2023 Update. Endocr Pract. 2023. See bibliography.md → aace-dm-2023. ↩
AGS. Guidelines for Improving the Care of Older Adults with Diabetes Mellitus: 2013 Update. J Am Geriatr Soc. 2013. See bibliography.md → ags-dm-2013. ↩↩↩↩↩
CMS. Medicare DSMT (MLN909381) and MNT (NCD 180.1) coverage. See bibliography.md → cms-dsmt. ↩↩
ICD-10: H25.x (age-related), H26.x (other / secondary) CCW prevalence (2022 Medicare FFS): 26.4% — rank 6 of 30 Category: Ophthalmic Primary associations consulted: AAO, USPSTF, NEI, CMS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | — | — | — |
| Imaging | — | — | — | — | — | Optical biometry (axial length, keratometry, anterior chamber depth) — once preoperatively for IOL calculation |
| Physical exam | — | — | — | Comprehensive medical eye evaluation (age ≥65); annual if comorbid diabetes regardless of cataract status | Comprehensive medical eye evaluation (age 55–64, asymptomatic) — every 1–3 yr | Post-op exam day 1 (or within 24–48 hr); post-op week 1–2; post-op month 1 |
| Functional / surveys | — | — | — | Best-corrected visual acuity (BCVA) + refraction, IOP, slit-lamp at each comprehensive exam | — | Functional impairment assessment (VF-14 or ADL-specific: reading, driving, TV, vocational / recreational tasks) for surgical-referral documentation |
A patient with a diagnosed non-surgical cataract should receive a comprehensive dilated medical eye evaluation every 1–2 years if age ≥65 (every 1–3 years if 55–64), per AAO Preferred Practice Pattern and NEI guidance; comorbid diabetes mandates annual dilated exams.214 At each visit BCVA with refraction, IOP, and slit-lamp biomicroscopy of the lens, anterior segment, and dilated fundus are standard.1 Surgical referral is not driven by a fixed visual-acuity threshold but by patient-specific functional impairment — inability to perform ADLs (reading, driving, TV, work, recreation) despite tolerable refractive correction — and is supported by Medicare LCDs and the AAO Cataract in the Adult Eye PPP.51 Standard post-operative follow-up is a three-visit cadence: day 1 (or within 24–48 hours for low-risk cases), week 1–2, and month 1 — checking VA, IOP, wound integrity, IOL position, and inflammation. PCPs should re-refer when patients report new or worsening functional vision impairment, post-operative symptoms (pain, vision loss, redness, photophobia), or have lapsed the 1–2 year interval.1
No laboratory monitoring is recommended for cataract surveillance.
American Academy of Ophthalmology. Cataract in the Adult Eye Preferred Practice Pattern. Ophthalmology. 2022;129(1):P1-P126. See bibliography.md → aao-cat-2021. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩
American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern. 2020 (reaffirmed). See bibliography.md → aao-eye-eval-2020. ↩↩↩↩
USPSTF. Screening for Impaired Visual Acuity in Older Adults: Recommendation Statement. JAMA. 2022;327(21):2123-2128 (Grade I). See bibliography.md → uspstf-vision-2022. ↩
National Eye Institute. Cataracts. NIH. See bibliography.md → nei-cat. ↩↩
CMS. Local Coverage Determinations for Cataract Surgery (L34413, L37027). See bibliography.md → cms-lcd-cataract. ↩↩↩↩↩
ICD-10: I20–I25 (chronic coronary disease spectrum; stable angina, prior MI, post-revascularization) CCW prevalence (2022 Medicare FFS): 21.8% — rank 7 of 30 Category: Cardiovascular Primary associations consulted: ACC/AHA (2023 CCD Guideline), USPSTF, CMS, NHLBI
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Lipid panel during titration (4–12 wk post statin start / change) | — | Lipid panel (stable), HbA1c (if DM), influenza + COVID-19 vaccination review | — | — |
| Imaging | — | — | — | — | — | Stress imaging (SPECT / PET / CMR / stress echo), coronary CTA, echocardiogram, or invasive angiography — only with new / worsening symptoms; routine surveillance is Class 3 (No Benefit) |
| Physical exam | BP, weight / BMI, physical activity assessment | — | — | — | — | — |
| Functional / surveys | Adherence review (aspirin 75–100 mg or DAPT through indicated window; high-intensity statin; β-blocker if indicated; ACEi / ARB if indicated; SGLT2i / GLP-1 RA in eligible); tobacco use + cessation counseling | — | — | PHQ-2 / PHQ-9 depression screen, ASCVD risk | — | Cardiac rehabilitation referral after MI, PCI, CABG, stable angina, valve repair / replacement, or transplant (up to 36 sessions over 36 weeks, CMS-covered) |
For a primary-care patient with clinically stable chronic coronary disease (CCD), the 2023 ACC/AHA CCD Guideline frames surveillance around guideline-directed medical therapy, lifestyle support, and risk-factor monitoring rather than routine repeat cardiac imaging.1 Outpatient visits are individualized — commonly every 4–6 months and at least annually once stable — and at each visit clinicians should measure BP (target <130/80 mm Hg), weight and physical activity, assess tobacco use, screen for depression with PHQ-2 / PHQ-9, and verify adherence to aspirin 75–100 mg (or DAPT through the post-PCI / ACS window), high-intensity statin, ACEi / ARB if indicated, and SGLT2i / GLP-1 RA in eligible patients.1 A lipid panel is checked 4–12 weeks after any statin change and then every 3–12 months, targeting ≥50% LDL-C reduction; the 2026 ACC/AHA Dyslipidemia Guideline adds an LDL-C <55 mg/dL secondary-prevention goal, with escalation to ezetimibe, bempedoic acid, or a PCSK9 inhibitor when unmet.2 Cardiac rehabilitation should be referred after MI, PCI, CABG, or for stable angina — CMS covers up to 36 sessions over 36 weeks.3 Routine surveillance stress testing, coronary CTA, echocardiography, or angiography is not recommended in asymptomatic stable patients (Class 3); escalate to stress imaging or angiography only when symptoms or functional capacity change despite optimized medical therapy.1
Virani SS et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148:e9-e119. See bibliography.md → accaha-ccd-2023. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026. See bibliography.md → accaha-dyslip-2026. ↩↩↩
CMS. National Coverage Determination 20.10: Cardiac Rehabilitation Programs. See bibliography.md → cms-cr-ncd. ↩↩
ICD-10: D50.x (iron-deficiency), D51.x (B12 deficiency), D52.x (folate deficiency), D53.x (other nutritional), D63.x (anemia in chronic disease) CCW prevalence (2022 Medicare FFS): 21.7% — rank 8 of 30 Category: Metabolic Primary associations consulted: KDIGO, ASH, AGA, AAFP, CDC, NIDDK, USPSTF
Anemia is a finding common to many underlying conditions; surveillance is subtype-specific. The sections below cover the dominant primary-care subtypes: iron deficiency anemia (IDA), anemia of chronic kidney disease, B12 / folate deficiency, and anemia in older adults / chronic disease.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | CBC + iron studies (ferritin, TSAT) q3 mo on ESA for CKD anemia; CBC q3 mo during first year of oral iron replacement | CBC screening Hgb (CKD G4–G5 non-dialysis) | CBC screening Hgb (CKD G3); follow-up CBC after iron repletion | CBC every 5–10 yr in women of childbearing age (CDC) | CBC + reticulocyte count, ferritin, B12, folate, eGFR, LDH / haptoglobin / bilirubin (workup); Hgb q2–4 wk on ESA initiation; CBC 1 mo after starting oral iron; reticulocyte 1 wk after B12 replacement; MMA / homocysteine 1 wk to 3 mo (B12 response); CBC at 8 wk (B12 replacement); GI evaluation (EGD + colonoscopy) for adult IDA in men and postmenopausal women |
| Imaging | — | — | — | — | — | — |
| Physical exam | — | — | — | — | — | Neurologic exam (vibration, proprioception, gait, cognition) at diagnosis and follow-up for B12 deficiency with neurologic findings |
| Functional / surveys | Symptom assessment (fatigue, dyspnea, exercise tolerance, pica, restless legs) during active treatment | — | — | — | — | Transfusion threshold assessment (restrictive Hgb 7–8 g/dL); avoid transfusion in CKD when possible to preserve transplant candidacy |
Primary-care surveillance of known anemia is subtype-specific. In iron deficiency anemia on oral iron, check a CBC at ~4 weeks (expect ≥1 g/dL Hgb rise), then every 3 months for one year, continue iron approximately 3 months after Hgb normalizes, and verify repleted stores with a follow-up ferritin.23 Persistent or recurrent IDA in adult men or postmenopausal women warrants GI evaluation (EGD + colonoscopy).36 In anemia of CKD, KDIGO 2012 anchors monitoring: screen Hgb annually in CKD G3 and every 6 months in G4–G5 non-dialysis; once on an ESA or HIF-PHI, monitor Hgb every 2–4 weeks during initiation and every 3 months in maintenance, with iron studies (ferritin, TSAT) every 3 months on ESA, targeting Hgb 10–11.5 g/dL while avoiding both Hgb <9 and >11.5 g/dL.1 For B12 deficiency on replacement, confirm response with reticulocytosis at 1 week, MMA / homocysteine normalization at 1 week to 3 months, and CBC normalization by 8 weeks; serial neurologic exams track recovery, and routine repeat B12 testing is not recommended once replacement is established.4 Folate deficiency monitoring parallels B12 (CBC at 8 weeks). For older adults with anemia of chronic disease or unexplained anemia, periodic CBC, iron studies, B12, eGFR, and TSH reclassify subtype; hemolysis labs (LDH, haptoglobin, bilirubin, peripheral smear) are added when Hgb drops without bleeding.5
KDIGO. Clinical Practice Guideline for Anemia in CKD. Kidney Int Suppl. 2012;2(4):279-335. See bibliography.md → kdigo-anemia-2012. ↩↩↩↩↩↩↩↩↩↩↩
Short MW, Domagalski JE. Iron Deficiency Anemia: Evaluation and Management. Am Fam Physician. 2013;87(2):98-104. See bibliography.md → aafp-ida-2013. ↩↩↩
Ko CW et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. 2020. See bibliography.md → aga-ida-2020. ↩↩↩↩↩↩↩
Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017;96(6):384-389. See bibliography.md → aafp-b12-2017. ↩↩↩↩↩↩↩
Bross MH et al. Anemia in Older Adults. Am Fam Physician. 2018;98(7):437-442. See bibliography.md → aafp-anemia-older-2018. ↩↩↩↩↩↩
CDC. Recommendations to Prevent and Control Iron Deficiency in the United States. MMWR Recomm Rep. 1998;47(RR-3):1-29. See bibliography.md → cdc-ida-1998. ↩↩↩
American Society of Hematology. Draft Recommendations for Diagnosis of Iron Deficiency (public comment 2025). See bibliography.md → ash-ida-2025-draft. ↩↩
NIDDK. Anemia in Chronic Kidney Disease. See bibliography.md → niddk-anemia. ↩
USPSTF. Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy. 2024. See bibliography.md → uspstf-ida-preg-2024. ↩
ICD-10: E03.x (primary hypothyroidism; includes congenital, autoimmune, post-treatment) CCW prevalence (2022 Medicare FFS): 21.3% — rank 9 of 30 Category: Metabolic Primary associations consulted: ATA, AACE, USPSTF, NIDDK
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | TSH every 4–8 wk during titration / dose change / formulation switch | TSH at 6 mo after stabilization (then transition to annual); TSH q6–12 mo while observing subclinical hypothyroidism | TSH (stable on levothyroxine); fasting lipid panel (untreated subclinical hypothyroidism) | — | Free T4 (dose adjustment, suspected non-adherence, central hypothyroidism, pregnancy); TPO antibodies once at subclinical-hypothyroidism workup; TSH q4 wk through ~20 wk gestation, then once between 26–32 wk; confirmatory repeat TSH at 2–3 mo for newly abnormal value before initiating therapy |
| Imaging | — | — | — | — | — | — |
| Physical exam | Weight, heart rate, blood pressure (each visit during titration); at least annually once stable | — | — | — | — | — |
| Functional / surveys | Symptom assessment — residual hypothyroidism + signs of overtreatment (tachycardia, weight loss, tremor) | — | — | — | — | — |
An adult with stable primary hypothyroidism on levothyroxine should have TSH checked 4–8 weeks after any dose change or formulation switch, again at approximately 6 months once stable, and annually thereafter — or sooner with new symptoms, pregnancy, weight change >10%, or addition of medications that affect absorption (PPI, calcium, iron, estrogen).1 The TSH target is 0.4–4.0 mIU/L for most adults, with an age-adjusted upward shift to 4–6 mIU/L in patients aged 70–80 and tolerance up to ~7 mIU/L in those ≥80 to avoid iatrogenic thyrotoxicosis, atrial fibrillation, and fracture.12 Free T4 is not required at every visit but is checked during titration, in suspected non-adherence, in central hypothyroidism, and routinely in pregnancy. Pregnancy demands immediate dose increase of ~20–30% at confirmation, TSH every 4 weeks through midgestation with a target below ~4.0 mIU/L (ideally between the lower reference limit and 2.5 mIU/L when treated), and reversion to pre-pregnancy dose postpartum with rechecking at 6 weeks.3 For untreated subclinical hypothyroidism, repeat TSH (with free T4 and TPO antibody) at 2–3 months to confirm persistence, then monitor every 6–12 months; check a fasting lipid panel and weigh treatment more strongly when TSH is >10 mIU/L, TPO Ab positive, or cardiovascular risk elevated.2 Each visit should include weight, heart rate, blood pressure, and a symptom review for both residual hypothyroidism and signs of overtreatment.
No routine imaging is recommended for surveillance of treated primary hypothyroidism.
Jonklaas J et al. Guidelines for the Treatment of Hypothyroidism — ATA Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751. See bibliography.md → ata-hypo-2014. ↩↩↩↩↩↩↩↩↩↩
Garber JR et al. Clinical Practice Guidelines for Hypothyroidism in Adults — AACE / ATA. Endocr Pract. 2012;18(6):988-1028. See bibliography.md → aace-ata-hypo-2012. ↩↩↩↩↩↩↩↩↩↩
Alexander EK et al. 2017 ATA Guidelines for Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid. 2017;27(3):315-389. See bibliography.md → ata-preg-2017. ↩↩↩↩↩
Jonklaas J et al. Evidence-Based Use of Levothyroxine / Liothyronine Combinations — ATA / BTA / ETA Consensus. Thyroid. 2021;31(2):156-182. See bibliography.md → ata-bta-eta-combo-2021. ↩↩
USPSTF. Final Recommendation Statement: Thyroid Dysfunction Screening. JAMA. 2015;313(12):1242. See bibliography.md → uspstf-thyroid-2015. ↩↩
ICD-10: F32.x (MDD single episode), F33.x (MDD recurrent), F31.x (bipolar disorder), F34.x (persistent mood) CCW prevalence (2022 Medicare FFS): 19.7% — rank 10 of 30 Category: Mental Health Primary associations consulted: USPSTF, APA, VA/DoD, AGS, CMS, SAMHSA, ADA/APA Consensus
CCW groups depression, bipolar disorder, and other mood disorders into a single category. Depression is the dominant component; bipolar-specific surveillance and medication-monitoring sections are flagged below.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Lithium level q3–6 mo (stable); valproate or carbamazepine level + CBC + LFTs q3–6 mo (stable); weight on SGA quarterly after first 12 wk | Lithium Cr + TSH q6–12 mo (stable); CBC + LFTs (valproate / carbamazepine stable) | BP + fasting glucose + lipids (SGA users, annually after the 12-wk visit) | — | Lithium level twice weekly during initiation, within 5–7 d of dose change; carbamazepine CBC + LFTs q2–4 wk first 2 mo; weight on SGA at baseline / 4 / 8 / 12 wk |
| Imaging | — | — | — | — | — | — |
| Physical exam | Weight / BMI (SGA users — baseline, 4, 8, 12 wk, then quarterly); BP (SGA users) | AIMS q6 mo (q3 mo high-risk) on antipsychotic therapy | — | BP + AIMS annually (SGA stable) | — | — |
| Functional / surveys | Adherence + adverse-effect review; suicide-risk reassessment (C-SSRS "Since Last Visit" or PHQ-9 item 9 follow-up) during active treatment | PHQ-9 monthly during acute treatment; every 2–4 wk in continuation; periodically in maintenance / recovery; GDS-15 or PHQ-9 in older adults; PHQ-9 / GDS q6 mo in nursing-home residents (2–4 wk post-admission, then q6 mo) | — | PHQ-2 / PHQ-9 screening per USPSTF 2023 for previously unscreened adults | — | MDQ at initial depression workup (rule out bipolar); CoCM / BHI registry tracking |
Primary-care monitoring of diagnosed depression follows a measurement-based-care framework: administer the PHQ-9 at baseline and at least monthly during acute treatment (weekly to biweekly in many systems), every 2–4 weeks during continuation, and periodically through maintenance, targeting response (≥50% PHQ-9 reduction) and remission (PHQ-9 ≤4).12 Suicide risk is reassessed at every visit during active treatment using PHQ-9 item 9 plus a structured tool such as the Columbia Suicide Severity Rating Scale "Since Last Visit," with more frequent contact in the first 4–12 weeks after starting or changing an antidepressant.16 Older adults are tracked with the GDS-15 or PHQ-9; nursing-home residents are reassessed 2–4 weeks after admission and every 6 months.7 Medication-specific monitoring varies by agent: SSRIs / SNRIs need baseline metabolic and tolerability review with reassessment at 2 weeks and at dose changes; lithium requires 12-hour trough levels (target 0.6–1.2 mEq/L; 0.4–0.8 in older adults) with creatinine and TSH every 6–12 months in stable patients (more often early); valproate and carbamazepine require periodic drug levels, CBC, and LFTs; second-generation antipsychotics used for bipolar or augmentation require ADA / APA metabolic monitoring of weight (baseline, 4 / 8 / 12 weeks, then quarterly), BP and fasting glucose and lipids (baseline, 12 weeks, then annually), and AIMS every 6 months.35 The MDQ should be administered when a new depressive episode is being evaluated to avoid missing bipolar disorder.3 Practices using the CMS Collaborative Care Model (CoCM, CPT 99492–99494) or Behavioral Health Integration (CPT 99484) embed all of this through a care-manager registry with monthly psychiatric caseload review.8
VA/DoD. Clinical Practice Guideline for Management of MDD. 2022. See bibliography.md → vadod-mdd-2022. ↩↩↩↩↩↩↩↩
APA. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. 2010. See bibliography.md → apa-mdd-2010. ↩
APA. Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd ed. 2002 (Guideline Watch 2005). See bibliography.md → apa-bipolar-2002. ↩↩↩↩↩↩↩↩↩↩↩
USPSTF. Screening for Depression and Suicide Risk in Adults: Recommendation Statement. JAMA. 2023;329(23):2057-2067. See bibliography.md → uspstf-depr-2023. ↩↩↩
ADA / APA / AACE / NAASO. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27(2):596-601. See bibliography.md → ada-apa-metab-2004. ↩↩↩↩↩↩
SAMHSA. Columbia Suicide Severity Rating Scale (C-SSRS). See bibliography.md → samhsa-cssrs. ↩↩
AGS / Hartford Institute. Try This: Geriatric Depression Scale (GDS). See bibliography.md → ags-gds. ↩↩
CMS. Behavioral Health Integration Services. MLN909432, 2026. See bibliography.md → cms-bhi-2026. ↩↩
ICD-10: N18.x (CKD stages 1–5), N19 (unspecified renal failure) CCW prevalence (2022 Medicare FFS): 18.7% — rank 11 of 30 Category: Renal Primary associations consulted: KDIGO, NKF KDOQI, USPSTF (insufficient evidence), CMS, ASN, NIDDK
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | BMP (Na, K, HCO3, BUN, Cr / eGFR) on RAAS / SGLT2i / MRA or eGFR <30 | Cr / eGFR + UACR for G4 (≈3×/yr), G3b A3, G5 (≈4×/yr); Ca / PO4 / PTH for G4 (q3–6 mo) and G5 (q1–3 mo) | Cr / eGFR + UACR for G3a A2, G3b A1–A2; Hgb (CBC) for G4–G5 non-dialysis; Ca / PO4 / PTH for G3a–G3b | Cr / eGFR + UACR for G1–G2 A1–A2 and G3a A1; Hgb (CBC) for G3; HbA1c ≥2×/yr if diabetic; vaccination review (pneumococcal, influenza, HBV, COVID-19) | — | Cystatin C with eGFRcr-cys when clinical decision hinges on accuracy; urinalysis at diagnosis or change in status; lipid panel once at diagnosis (no routine repeat); K + Cr at 2–4 wk after starting / titrating ACEi / ARB / SGLT2i / MRA; iron studies if anemia evaluated; 25-OH vitamin D at baseline; alkaline phosphatase q12 mo G4–G5 |
| Imaging | — | — | — | — | — | — |
| Physical exam | Standardized office BP (5-min rest, validated cuff, multi-step protocol, average of readings); target SBP <120 mm Hg | — | — | — | — | — |
| Functional / surveys | Medication reconciliation (NSAID avoidance, contrast safety, dose adjustment); lifestyle counseling (Na <2 g/d, ≥150 min/wk activity, plant-rich diet, smoking cessation, weight) | — | — | KFRE 2- and 5-year risk recalculation | — | Nephrology referral when 5-yr KFRE ≥3–5%, 2-yr ≥10%, eGFR <30, persistent A3 albuminuria, refractory hypertension / hyperkalemia / anemia / CKD-MBD, or unexplained decline; transplant / dialysis-access workup |
Primary-care surveillance of established CKD is driven by the KDIGO 2024 heat map: combine current eGFR (race-free CKD-EPI 2021 creatinine equation, adding cystatin C when clinical decisions hinge on accuracy) with UACR, then plot on the G1–G5 / A1–A3 grid.1 Low-risk patients (G1–G2 A1) need annual eGFR + UACR; moderate-risk (e.g., G1–G2 A2, G3a A1) twice yearly; high-risk (G3a A2, G3b A1–A2, any G1–G2 A3) two to three times yearly; very-high-risk (G3b A3, all G4, all G5) three to four times yearly, with BP, electrolytes, and bicarbonate at each draw.1 At G3a add CKD-MBD labs — calcium, phosphate, PTH, alkaline phosphatase every 6–12 months, tightening to every 3–6 months at G4 and every 1–3 months at G5.4 Screen hemoglobin annually in G3 and twice yearly in G4–G5 non-dialysis (KDIGO 2012 Anemia in CKD).5 Check a lipid panel once at diagnosis for risk stratification, then "fire-and-forget" — start a statin (or statin / ezetimibe) in all adults ≥50 with eGFR <60 without routinely retesting LDL.6 In diabetics, HbA1c twice yearly (quarterly if unstable), individualized 6.5–8.0%, with SGLT2i (eGFR ≥20), GLP-1 RA for residual cardiometabolic risk, and non-steroidal MRA (finerenone) for persistent albuminuria with serum K <5.3 Target standardized office SBP <120 mm Hg.2 ACEi or ARB at maximum tolerated dose in A2–A3, continued even when eGFR falls <30 unless intolerable. Recheck K and creatinine 2–4 weeks after starting / titrating RAAS, SGLT2i, or MRA. Refer to nephrology when 5-year KFRE ≥3–5%, 2-year ≥10%, eGFR <30, persistent A3 albuminuria, or refractory complications.1
No routine imaging is recommended for surveillance.1
KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. See bibliography.md → kdigo-ckd-2024. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
KDIGO. 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. Kidney Int. 2021. See bibliography.md → kdigo-bp-2021. ↩↩↩↩↩
KDIGO. 2022 Clinical Practice Guideline for Diabetes Management in CKD. Kidney Int. 2022. See bibliography.md → kdigo-dm-2022. ↩↩
KDIGO. 2017 Clinical Practice Guideline Update for Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. Kidney Int Suppl. 2017. See bibliography.md → kdigo-mbd-2017. ↩↩↩↩↩
KDIGO. Clinical Practice Guideline for Anemia in CKD. Kidney Int Suppl. 2012. See bibliography.md → kdigo-anemia-2012. ↩↩↩↩
KDIGO. 2013 Clinical Practice Guideline for Lipid Management in CKD. Kidney Int Suppl. 2013. See bibliography.md → kdigo-lipid-2013. ↩↩↩
Grundy SM et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. See bibliography.md → accaha-chol-2018. ↩
ICD-10: H40.x (glaucoma — POAG, NTG, angle-closure, suspect) CCW prevalence (2022 Medicare FFS): 15.0% — rank 12 of 30 Category: Ophthalmic Primary associations consulted: AAO, USPSTF, NEI, Glaucoma Research Foundation
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | — | — | — |
| Imaging | — | — | OCT of peripapillary RNFL / optic nerve head / macular GCC (every 6–12 mo; complementary to visual field) | OCT (stable, annual) | — | Stereo disc photography or imaging at baseline + as indicated |
| Physical exam | Tonometry (IOP); medication adherence + ocular surface assessment | Comprehensive eye exam (every 1–3 mo if progressing despite control; every 1–2 mo if progressing and uncontrolled) | Comprehensive eye exam (every 3–6 mo if recently controlled) | Comprehensive eye exam (every 6–12 mo if stable target IOP, no progression >6 mo); gonioscopy (every 1–5 yr or with change) | — | Central corneal thickness (pachymetry) at baseline; post-LPI / post-surgical follow-up |
| Functional / surveys | — | — | Automated perimetry (Humphrey 24-2 or 30-2; every 6–12 mo); 10-2 for advanced disease | Visual field (stable) | — | Up to 2×/year visual field in first 2 years post-diagnosis (≥6 tests in 2 yr to establish progression rate); target IOP setting + adjustment |
USPSTF (2022, Grade I) finds insufficient evidence to recommend for or against routine primary-care screening for glaucoma in asymptomatic adults — but does not say "don't refer."3 NEI and AAO recommend a baseline comprehensive dilated eye exam at age 40 for all adults, and every 1–2 years for higher-risk groups (Black adults ≥40, all adults ≥60, Hispanic / Latino ≥60, family history of glaucoma, diabetes); PCPs refer these populations on that cadence and send any patient with elevated IOP, suspicious cup-to-disc ratio, or family history for a glaucoma-specific evaluation.41 Once a patient carries a diagnosis of POAG, NTG, or angle-closure glaucoma, ophthalmology owns surveillance per the AAO POAG PPP 2025 follow-up grid: every 6–12 months if target IOP achieved and stable >6 months; every 3–6 months if recently controlled; every 1–3 months if progressing despite control; and every 1–2 months if progressing and uncontrolled.1 Target IOP is individualized at 20–30% below untreated baseline, with stricter targets for advanced disease (also reflected in MIPS Measure #141, which requires 20% IOP reduction or documented plan of care).15 The PCP's continuing role is reinforcing drop adherence, reviewing systemic effects of topical β-blockers (bradycardia, bronchospasm) and prostaglandin analogs, flagging missed ophthalmology visits, and recognizing red flags — acute eye pain with halos / nausea (acute angle closure, emergent referral), rapid vision loss, or new field defect.
No laboratory monitoring is recommended for glaucoma surveillance.
AAO. Primary Open-Angle Glaucoma Preferred Practice Pattern. 2025. See bibliography.md → aao-poag-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
AAO. Primary Angle-Closure Disease Preferred Practice Pattern. 2025. See bibliography.md → aao-angle-2025. ↩↩
USPSTF. Screening for Primary Open-Angle Glaucoma: Recommendation Statement. JAMA. 2022;327(20):1992-1997. See bibliography.md → uspstf-glaucoma-2022. ↩↩
National Eye Institute. Statement on Detection of Glaucoma and Adult Vision Screening. See bibliography.md → nei-glaucoma. ↩↩↩
CMS / MIPS Quality Measure #141. Primary Open-Angle Glaucoma: Reduction of IOP by 20% or Documentation of Plan of Care. 2025. See bibliography.md → mips-141. ↩↩↩
ICD-10: I48.0–I48.92 (paroxysmal, persistent, chronic, atypical, typical flutter) CCW prevalence (2022 Medicare FFS): 14.1% — rank 13 of 30 Category: Cardiovascular Primary associations consulted: ACC/AHA/ACCP/HRS, USPSTF, CMS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | INR on warfarin (at least monthly once stable; every 3–6 mo as a floor); BMP / Cr / eGFR / hepatic on DOAC at lower CrCl (≈every CrCl/10 months), age ≥75, frailty | — | Cr / eGFR (DOAC stable); HbA1c (if DM); lipid panel; CBC (Hgb) for occult bleeding | — | INR weekly during initiation / change / interacting drug or illness; Cr / hepatic / CBC for symptoms or bleeding |
| Imaging | ECG / rhythm strip if symptom or rhythm change | — | — | — | — | TTE at diagnosis; repeat with clinical change / new murmur / pre-procedure; TEE / cardiac CT pre-cardioversion (if <3 wk OAC) and pre-ablation / pre-LAAO; ambulatory rhythm monitoring (Holter / patch / event / ILR) post-ablation, symptom-driven |
| Physical exam | BP, HR + rhythm assessment, weight / BMI | — | — | — | — | — |
| Functional / surveys | Symptoms (EHRA / CCS-SAF or palpitations / dyspnea / fatigue / exercise tolerance); physical-activity counseling; alcohol; tobacco | — | — | CHA2DS2-VASc reassessment; HAS-BLED reassessment for modifiable bleeding risk; OSA screen (annual at minimum); CPAP adherence | — | LAAO (Watchman) candidacy reassessment when OAC contraindicated or major bleed; structured weight-loss program for BMI ≥27 |
Primary-care monitoring of established atrial fibrillation / flutter is anchored in annual (and event-driven) reassessment of CHA2DS2-VASc thromboembolic risk and modifiable bleeding-risk factors via HAS-BLED (used to identify, not to withhold, anticoagulation).1 DOACs are preferred over warfarin in non-valvular AF; warfarin patients require ongoing INR monitoring (target 2.0–3.0; goal time-in-therapeutic-range >70%), with conversion to a DOAC considered when TTR cannot be maintained.1 DOAC patients need baseline and at least annual creatinine / eGFR (more frequent — approximately every CrCl/10 months — at lower CrCl, age ≥75, frailty, or acute illness), plus periodic hepatic and hemoglobin assessment; FDA-labeled dosing must be used (non-evidence-based dose reductions are explicitly discouraged, Class 3 Harm).1 Every visit should include pulse / rhythm assessment with ECG when needed; rate control accepts resting HR <110 bpm (lenient, per RACE II) when symptoms are controlled and LV function preserved, with stricter HR <80 bpm if symptomatic or tachycardia-mediated cardiomyopathy suspected. TTE is obtained at diagnosis and repeated for clinical change or pre-procedure. Post-ablation patients are followed with a 3-month blanking period before judging success, with symptom-driven ambulatory rhythm monitoring; OAC continues based on CHA2DS2-VASc regardless of apparent ablation success.1 The 2023 guideline elevates lifestyle and risk-factor modification to a co-equal pillar: ≥10% weight loss for BMI ≥27, ~210 min/wk moderate-vigorous exercise, BP <130/80, optimized glycemic and lipid management, alcohol minimization, tobacco cessation, and OSA screening / treatment.
Joglar JA et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1-e156. See bibliography.md → accaha-af-2023. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
USPSTF. Screening for Atrial Fibrillation: Recommendation Statement. JAMA. 2022;327(4):360-367. See bibliography.md → uspstf-af-2022. ↩
CMS. National Coverage Determination 20.34: Percutaneous Left Atrial Appendage Closure. See bibliography.md → cms-laac-ncd. ↩↩
ICD-10: J44.x (COPD; with / without exacerbation; with emphysema; with chronic bronchitis) CCW prevalence (2022 Medicare FFS): 12.8% — rank 14 of 30 Category: Respiratory Primary associations consulted: GOLD, USPSTF, ATS, CMS, CDC, ALA
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | Spirometry (post-bronchodilator FEV1 / FVC and FEV1 % predicted — at diagnosis + at least annually to detect rapid decliners); vaccination review (influenza annually; SARS-CoV-2 updated per CDC; PCV20 or PCV21 single dose; RSV ≥60 or comorbid; Tdap; zoster ≥50) | — | Alpha-1 antitrypsin (AAT) once in lifetime at diagnosis; blood eosinophil count at baseline + when considering ICS escalation / de-escalation; ABG when SpO2 ≤92% or for LTOT qualification |
| Imaging | — | — | — | — | — | Chest CT (low-dose) for persistent exacerbation, suspected lung cancer / emphysema / bronchiectasis; annual LDCT lung-cancer screening if 20+ pack-year smoking history, age 50–80 (USPSTF Grade B); LVR / transplant evaluation |
| Physical exam | Pulse oximetry (SpO2); smoking status + cessation counseling; BMI / nutritional status | — | — | — | — | ECG / cardiovascular risk assessment at baseline; reassess after exacerbations (GOLD 2025 cardiopulmonary risk emphasis) |
| Functional / surveys | CAT (COPD Assessment Test); mMRC dyspnea; exacerbation history (12-mo lookback); GOLD A / B / E reclassification | — | — | Pulmonary-rehab eligibility review (after exacerbation hospitalization initiate within 3 wk of discharge; stable mMRC ≥2 / CAT ≥10) | — | 6-Minute Walk Test at pulmonary-rehab entry / exit; LTOT assessment (resting PaO2 ≤55 / SpO2 ≤88 — or ≤60 / 88 with cor pulmonale / polycythemia — confirm twice ≥3 wk apart) |
US primary-care COPD surveillance under GOLD 2025 emphasizes structured, symptom- and exacerbation-driven monitoring rather than dense laboratory testing.1 At every visit, clinicians should assess symptoms with the CAT (≥10 = "more symptoms") and mMRC dyspnea scale (≥2 triggering pulmonary-rehab referral), document moderate and severe exacerbations over the past 12 months to reclassify GOLD A / B / E groupings, measure SpO2, and reinforce smoking cessation.1 Spirometry is performed at diagnosis and at least annually thereafter (or with significant clinical change) to identify rapid decliners. Alpha-1 antitrypsin testing should be obtained once in every COPD patient, and a baseline blood eosinophil count informs ICS and biologic (dupilumab) decisions, with ≥300 cells/µL favoring ICS / biologic therapy and <100 cells/µL arguing against ICS.1 Vaccinations (annual influenza, updated SARS-CoV-2, PCV20 or PCV21, RSV if ≥60 or comorbid, Tdap, zoster) follow CDC ACIP and should be reviewed yearly. Pulmonary rehabilitation should be initiated within 3 weeks of any exacerbation-related hospitalization (ATS 2023 strong recommendation) and offered to stable patients with mMRC ≥2; CMS NCD 240.8 covers up to 36 sessions for GOLD II–IV COPD.26 Long-term oxygen therapy is initiated when stable resting PaO2 ≤55 mm Hg or SpO2 ≤88% (or ≤60 mm Hg / 88% with cor pulmonale or polycythemia), confirmed on two measurements ≥3 weeks apart, with a treatment target SpO2 88–92%.13
GOLD. 2025 Global Strategy for Prevention, Diagnosis and Management of COPD. See bibliography.md → gold-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Rochester CL et al. Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official ATS Clinical Practice Guideline. Am J Respir Crit Care Med. 2023;208(4):e7-e26. See bibliography.md → ats-pr-2023. ↩↩↩↩
Jacobs SS et al. Home Oxygen Therapy for Adults with Chronic Lung Disease: ATS Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121-e141. See bibliography.md → ats-ltot-2020. ↩↩
USPSTF. Screening for Chronic Obstructive Pulmonary Disease: Reaffirmation Recommendation Statement. JAMA. 2022;327(18):1806-1811 (Grade D). See bibliography.md → uspstf-copd-2022. ↩
USPSTF. Screening for Lung Cancer: Recommendation Statement. 2021. See bibliography.md → uspstf-lung-2021. ↩
CMS. National Coverage Determination 240.8: Pulmonary Rehabilitation Services. See bibliography.md → cms-pr-ncd. ↩↩↩
ICD-10: I50.x (heart failure — systolic, diastolic, mixed; with / without RHF) CCW prevalence (2022 Medicare FFS): 12.3% — rank 15 of 30 Category: Cardiovascular Primary associations consulted: AHA/ACC/HFSA, HFSA, CMS, NHLBI
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | BMP (Na, K, BUN, Cr / eGFR, Mg) within 1–2 wk after starting / titrating ACEi / ARB / ARNI / MRA / SGLT2i / diuretic; every 3–6 mo when stable | BMP every 3–6 mo (stable) | Iron studies (ferritin, TSAT) — HFrEF periodic; lipid panel; HbA1c (if DM); TSH; CBC; urinalysis if clinically indicated | — | Initial labs at diagnosis (CBC, urinalysis, BMP, LFTs, lipid, TSH, HbA1c, iron studies); BNP / NT-proBNP at presentation, admission, and predischarge; troponin with acute change |
| Imaging | — | — | — | — | — | TTE at diagnosis; repeat with unexplained clinical change, after intervention likely to alter LV function (3–6 mo after GDMT optimization for HFimpEF), or pre-procedure; ECG at initial eval + with symptom change or device consideration |
| Physical exam | BP, HR, weight, JVP, peripheral edema, lung exam (volume status); NYHA functional class | — | — | — | — | — |
| Functional / surveys | NYHA class; weight diary / RPM review | KCCQ (Kansas City Cardiomyopathy Questionnaire) every 3–6 mo or with clinical change | — | Depression screen (PHQ-2 → PHQ-9); cardiac-rehab participation review | — | Cardiac-rehab referral (CMS NCD 20.10.1: LVEF ≤35%, NYHA II–IV, OMT ≥6 wk, no hospitalization / procedure within 6 wk); RPM / CardioMEMS as appropriate |
US primary-care surveillance of established adult heart failure (HFrEF, HFmrEF, HFpEF) under the 2022 AHA/ACC/HFSA guideline (with 2023 / 2024 ACC ECDPs and 2024 Performance Measures) follows a structured cadence.12 Every visit captures BP, HR, weight, volume status (JVP / edema / lungs), and NYHA class; KCCQ is recommended at baseline and serially to track patient-reported health status (Class 2a).1 During GDMT initiation or titration of ACEi / ARB / ARNI / MRA / SGLT2i or diuretic, a BMP (Na, K, Cr / eGFR, BUN, Mg) is checked within 1–2 weeks, then every 3–6 months once stable; stable patients are otherwise seen every 3–6 months.12 Initial workup includes CBC, BMP, LFTs, lipids, TSH, HbA1c, iron studies (ferritin / TSAT), urinalysis, ECG, and 2D echocardiogram with Doppler (Class 1).1 BNP or NT-proBNP is Class 1 for diagnosis and for hospital admission / predischarge prognostication; outpatient serial measurement to titrate therapy is not endorsed but values inform prognosis and decongestion. Iron studies are repeated periodically in HFrEF; IV iron is indicated when ferritin <100 ng/mL or 100–300 with TSAT <20%. Echocardiography is repeated only with unexplained clinical change or after an intervention expected to alter LV function (e.g., to document HFimpEF after 3–6 months of GDMT) — routine surveillance imaging is not recommended. CMS covers cardiac rehabilitation for stable HFrEF (LVEF ≤35%, NYHA II–IV) under NCD 20.10.1, and supports RPM (weight, BP, PA pressure) for chronic HF management.4
Heidenreich PA et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. See bibliography.md → accaha-hf-2022. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Maddox TM et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF. J Am Coll Cardiol. 2024;83(15):1444-1488. See bibliography.md → acc-hfref-ecdp-2024. ↩↩↩
Kittleson MM et al. 2023 ACC Expert Consensus Decision Pathway on Management of HFpEF. J Am Coll Cardiol. 2023;81(18):1835-1878. See bibliography.md → acc-hfpef-ecdp-2023. ↩
CMS. NCD 20.10.1: Cardiac Rehabilitation Programs for Chronic Heart Failure. See bibliography.md → cms-hf-cr. ↩↩
Lichtman JH et al. Depression and Coronary Heart Disease — AHA Science Advisory. Circulation. 2008;118:1768-1775. See bibliography.md → aha-depr-cvd-2008. ↩
ICD-10: M80.x (osteoporosis with current pathologic fracture), M81.x (osteoporosis without fracture) CCW prevalence (2022 Medicare FFS): 11.5% — rank 16 of 30 Category: Musculoskeletal Primary associations consulted: USPSTF, AACE/ACE, BHOF (formerly NOF), Endocrine Society, ACP, CMS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Serum Ca prior to each IV zoledronate or denosumab dose | — | 25-OH vitamin D (after repletion, then annually); calcium-intake assessment | — | Baseline secondary-causes workup (Ca, 25-OH vit D, PTH, alk phos, Cr / eGFR, P, Mg, TSH, CBC, 24-hr urine Ca; SPEP / celiac / testosterone if indicated); CTX or P1NP bone-turnover markers (baseline + 3–6 mo after starting / changing therapy, and during drug holiday) |
| Imaging | — | — | — | — | Central DXA every 2 years (Medicare-coverable when medically necessary; USPSTF acknowledges 4–8 yr intervals may suffice in low-risk untreated women) | Central DXA every 1–2 yr on therapy (AACE) or 1–3 yr (Endo Society) until stable, then longer intervals; Vertebral Fracture Assessment (VFA) if height loss ≥1.5 in historical / ≥0.8 in prospective, kyphosis, recent low-trauma fracture, chronic glucocorticoids, or T-score ≤ −2.5 |
| Physical exam | — | — | — | Standing height measurement; fall-risk screen (Timed Up and Go, fall history, medication review, vision, gait / balance) | — | Height drop ≥2 cm prospective or ≥4 cm historical triggers VFA |
| Functional / surveys | — | — | Denosumab continuity check (no gap >7 mo; if discontinuing, transition to bisphosphonate to prevent rebound vertebral fractures) | FRAX 10-yr fracture risk recalculation; calcium intake (target 1000 mg/d men 50–70, 1200 mg/d women ≥51 / men ≥71; vit D 800–1000 IU/d) | — | Drug-holiday eligibility reassessment after 5 yr oral bisphosphonate or 3 yr IV zoledronate; anabolic-to-antiresorptive sequencing at end of teriparatide / abaloparatide (18–24 mo) or romosozumab (12 mo) |
Primary-care osteoporosis surveillance combines BMD imaging, fracture-risk recalibration, drug-class-specific safety checks, and lifestyle / fall assessment. Per USPSTF 2025 (Grade B), screening DXA is recommended for women ≥65 and for postmenopausal women <65 at increased risk; men remain an I-statement.1 Once on pharmacotherapy, AACE 2020 endorses repeating central DXA every 1–2 years until stable, with longer intervals thereafter; the Endocrine Society 2019 supports 1–3 years; ACP 2023 and BHOF 2022 take a more skeptical stance on within-treatment DXA because fracture-risk reduction is decoupled from measured BMD change.2356 FRAX should be recalculated when risk factors change and at drug-holiday decision points. Drug-class monitoring is critical: denosumab must not be discontinued without immediate bisphosphonate transition (rebound vertebral fractures); oral bisphosphonates warrant drug-holiday consideration after 5 years (IV zoledronate after 3 years) in low-to-moderate-risk patients; anabolic agents (teriparatide, abaloparatide, romosozumab) require sequencing to an antiresorptive at course end.32 All patients need baseline secondary-causes labs (Ca, 25-OH vit D, PTH, alkaline phosphatase, creatinine, TSH, ±24-hr urine Ca), pre-dose calcium checks for IV antiresorptives, and ongoing calcium 1000–1200 mg/d plus vitamin D 800–1000 IU/d. Annual height measurement, fall-risk screening, and vertebral fracture assessment when triggered round out primary-care surveillance. CTX / P1NP markers offer an inexpensive adherence and response check 3–6 months after therapy change and during drug holidays.
USPSTF. Screening for Osteoporosis to Prevent Fractures: Recommendation Statement. JAMA. 2025;333(6):498-508. See bibliography.md → uspstf-osteo-2025. ↩↩↩↩↩↩
Camacho PM et al. AACE/ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. See bibliography.md → aace-osteo-2020. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Eastell R et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. See bibliography.md → endo-osteo-2019. ↩↩↩↩↩↩↩↩↩↩↩
Shoback D et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3):587-594. See bibliography.md → endo-osteo-2020-update. ↩
Qaseem A et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures: Living Clinical Guideline From ACP. Ann Intern Med. 2023;176(2):224-238. See bibliography.md → acp-osteo-2023. ↩↩↩↩↩
LeBoff MS et al. The Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2022;33(10):2049-2102. See bibliography.md → bhof-2022. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
CMS. NCD 150.3: Bone (Mineral) Density Studies. See bibliography.md → cms-dxa-ncd. ↩↩
ICD-10: C61 (malignant neoplasm of prostate) CCW prevalence (2022 Medicare FFS): 9.9% (males only) — rank 17 of 30 Category: Cancer (urologic; males only) Primary associations consulted: NCCN, AUA/SUO, ASCO, ASTRO, USPSTF
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | PSA on active surveillance (q3–6 mo); testosterone on ADT (q3–6 mo, target <50 ng/dL); PSA on ADT / AR-pathway inhibitor; abiraterone LFTs / K+ / BP (q2 wk × 3 mo then monthly); mCRPC baseline labs (CBC, CMP, ALP, LDH, Hgb) each cycle | PSA post-curative (q6–12 mo first 5 yr) | PSA post-curative (after 5 yr stable, annual); lipid panel + fasting glucose / HbA1c (on ADT); Ca / 25-OH vit D (on ADT, on bone-modifying agents) | DEXA on ADT (baseline + every 1–2 yr); MRI prostate on AS (every 1–3 yr) | Confirmatory biopsy on AS at 6–12 mo, then every 2–5 yr or as triggered; PSMA PET/CT at BCR with negative conventional imaging or for unfavorable / high-risk staging; conventional CT abd/pelvis + Tc-99m bone scan at BCR / progression; imaging in mCRPC at least annually; eGFR / Cr per agent |
| Imaging | — | — | — | — | DEXA on ADT (every 1–2 yr); mpMRI on AS (every 1–3 yr) | CT abd/pelvis + bone scan at BCR / progression; PSMA PET/CT; mCRPC imaging q6–12 mo (sooner if PSADT short or symptoms) |
| Physical exam | BP and cardiovascular assessment on ADT / AR-pathway inhibitor | — | — | DRE on active surveillance; DRE post-curative (may omit if PSA undetectable post-RP) | — | — |
| Functional / surveys | Distress screen (NCCN Distress Thermometer); hot flashes / vasomotor symptoms (on ADT); mood / depression; sexual function review | — | — | Urinary continence (EPIC, IPSS); erectile function (SHIM / IIEF); bowel function post-RT; age-appropriate second-cancer screening (CRC, skin) per USPSTF | — | Urology referral for bothersome incontinence or persistent rectal bleeding |
The dominant rhythm of prostate cancer surveillance is PSA every 3–6 months with risk-adapted intensification. On active surveillance, NCCN v1.2025 and AUA/ASTRO 2022 endorse PSA every 6 months (often q3–6 mo in the first year), annual DRE, multiparametric MRI roughly every 1–3 years, and a confirmatory biopsy within 6–12 months of diagnosis followed by surveillance biopsies every 2–5 years or when triggered by PSA kinetics, new DRE findings, or rising PI-RADS.12 After curative therapy, PSA is checked every 6–12 months for 5 years and then annually; the operative definitions of recurrence are PSA ≥0.2 ng/mL (confirmed) post-prostatectomy and PSA nadir + 2 ng/mL (Phoenix) post-radiation. PSMA PET is now first-line at biochemical recurrence when conventional imaging is negative.31 For men on ADT or AR-pathway inhibitors (apalutamide, enzalutamide, darolutamide, abiraterone), primary-care-relevant monitoring includes serum testosterone (goal <50 ng/dL), DEXA at baseline and every 1–2 years with FRAX-guided bisphosphonate or denosumab use, calcium / vitamin D replacement, annual lipid and glycemic screening, blood pressure at every visit, and structured assessment of hot flashes, fatigue, mood, sexual function, and cognition.36 In mCRPC, imaging is performed at least annually even with stable PSA. Survivorship priorities the PCP owns include urinary and sexual function, depression and PSA anxiety, cardiometabolic risk on ADT, bone health, and continued age-appropriate screening for second cancers.67
NCCN. Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 1.2025. See bibliography.md → nccn-pca-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Eastham JA et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. J Urol. 2022. See bibliography.md → aua-astro-pca-2022. ↩↩↩↩↩↩↩↩↩↩
Lowrance W et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). See bibliography.md → aua-apc-2023. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Wei JT et al. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023). See bibliography.md → aua-pca-detection-2023. ↩
USPSTF. Screening for Prostate Cancer: Recommendation Statement. JAMA. 2018;319(18):1901-1913. See bibliography.md → uspstf-pca-2018. ↩
Skolarus TA et al. American Cancer Society Prostate Cancer Survivorship Care Guidelines; ASCO endorsement. J Clin Oncol. 2015. See bibliography.md → ascoacs-pca-2015. ↩↩↩↩↩↩↩↩↩↩↩
Nekhlyudov L et al. Survivorship Care for Adults With a History of Adult-Onset Cancer: ASCO Guideline Update. 2024. See bibliography.md → asco-surv-2024. ↩↩
ICD-10: F01.x (vascular dementia), F02.x (dementia in other diseases — DLB, FTD), G31.x (other degenerative diseases — DLB, FTD, PSP) CCW prevalence (2022 Medicare FFS): 8.7% — rank 18 of 30 Category: Neurologic Primary associations consulted: AAN, AGS, APA, USPSTF, CMS, Alzheimer's Association
CCW separates Alzheimer's disease (rank 22) from non-Alzheimer's dementia. This monograph covers vascular dementia, dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and mixed dementias. Surveillance overlaps substantially with Alzheimer's care; subtype-specific cautions are flagged.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | Caregiver burden assessment (Zarit) every 6–12 mo | TSH, vitamin B12 at diagnosis (and as clinically indicated); CMP / CBC for delirium workup | — | Repeat labs only with acute cognitive worsening (rule out delirium) |
| Imaging | — | — | — | — | — | Non-contrast MRI preferred (CT if MRI contraindicated) once at diagnosis; repeat only with atypical course or focal change |
| Physical exam | Medication review with AGS Beers Criteria (anticholinergic burden, sedative-hypnotics, antipsychotics); antipsychotic appropriateness review if on agent | — | — | Fall-risk assessment (Timed Up & Go, gait / balance); driving safety evaluation (CDR-based) | — | Antipsychotic taper attempt within 4 months of initiation (APA) |
| Functional / surveys | Neuropsychiatric / behavioral symptom screen (NPI-Q, BEHAVE-AD, PHQ-2); vascular risk-factor control (BP, lipids, glycemia, smoking, AFib anticoagulation) | — | — | Cognitive testing (MoCA, Mini-Cog, MMSE, or SLUMS); ADL / IADL (Katz / Lawton-Brody); dementia staging (FAST or CDR); depression screen (GDS-15 or PHQ-9); advance care planning / goals-of-care discussion; CMS Cognitive Assessment & Care Plan Service (CPT 99483, billable every 180 days) | — | Health-related social needs (HRSN) screening; GUIDE Model enrollment for community-dwelling patients |
US guidelines converge on a structured longitudinal surveillance pattern for established non-Alzheimer's dementia anchored by the annual Medicare Annual Wellness Visit (mandated cognitive impairment detection) and, when indicated, the CMS Cognitive Assessment & Care Plan Service (CPT 99483, billable every 180 days), which packages the core surveillance bundle.8 The bundle includes cognitive testing (MoCA / Mini-Cog / MMSE / SLUMS), ADL / IADL functional review, FAST or CDR staging, neuropsychiatric symptom screen (NPI-Q, BEHAVE-AD, or PHQ-2), high-risk medication reconciliation under AGS Beers 2023 (anticholinergics, benzodiazepines, antipsychotics), home and driving safety evaluation, caregiver-needs assessment, advance care planning, and a written care plan.85 AAN practice parameters (dementia diagnosis 2001, reaffirmed 2024; MCI 2018; driving 2010) and the 2024 Alzheimer's Association DETeCD-ADRD guideline support cognitive testing at least annually, depression screening (GDS / PHQ-9), TSH / B12 at diagnosis, and one-time structural MRI / CT.16 The APA 2016 antipsychotic guideline frames behavioral-symptom management with non-pharmacologic first-line care, low-dose second-generation antipsychotics only for severe / dangerous symptoms, attempted taper within 4 months, and avoidance in DLB due to neuroleptic sensitivity.4 CMS's GUIDE Model (July 2024–2032) layers care navigation, 24/7 caregiver support, respite, and HRSN screening on top of the visit-based surveillance.9 Fall risk (TUG), driving risk (CDR-based), and vascular risk-factor control receive distinct emphasis in vascular and DLB phenotypes.
Knopman DS et al. Practice Parameter: Diagnosis of Dementia (evidence-based review). AAN. Neurology. 2001;56:1143-1153. Reaffirmed October 2024. See bibliography.md → aan-dementia-2001. ↩↩↩↩↩↩↩
Petersen RC et al. Practice Guideline Update Summary: Mild Cognitive Impairment. AAN. Neurology. 2018;90:126-135 (retired Feb 2024). See bibliography.md → aan-mci-2018. ↩↩↩↩
Iverson DJ et al. Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia. AAN. Neurology. 2010;74:1316-1324. See bibliography.md → aan-driving-2010. ↩↩
Reus VI et al. APA Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry. 2016;173(5):543-546. See bibliography.md → apa-dementia-antipsy-2016. ↩↩↩↩
American Geriatrics Society. 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. See bibliography.md → ags-beers-2023. ↩↩↩↩
Atri A et al. Alzheimer's Association Clinical Practice Guideline DETeCD-ADRD: Primary Care Executive Summary. Alzheimer's Dement. 2025. See bibliography.md → alz-detecd-2024. ↩↩↩↩↩↩↩↩
USPSTF. Screening for Cognitive Impairment in Older Adults: Recommendation Statement. JAMA. 2020;323(8):757-763. See bibliography.md → uspstf-cog-2020. ↩
CMS. Cognitive Assessment & Care Plan Services (CPT 99483). See bibliography.md → cms-cog-99483. ↩↩↩↩↩↩↩
CMS Innovation Center. GUIDE (Guiding an Improved Dementia Experience) Model. 2024-2032. See bibliography.md → cms-guide-2024. ↩↩↩↩
CMS. Medicare Annual Wellness Visit cognitive detection requirement. See bibliography.md → cms-awv. ↩↩
ICD-10: C50.x (malignant neoplasm of breast) CCW prevalence (2022 Medicare FFS): 8.2% (females only) — rank 19 of 30 Category: Cancer (females only; CCW Medicare population is overwhelmingly older women, often post-treatment for stage I-III disease on endocrine therapy) Primary associations consulted: ASCO/ACS Survivorship, NCCN, USPSTF, ACOG, ASCO Cardio-Oncology
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | LFTs / cardiotoxicity labs on active chemotherapy | — | Lipid panel + Ca / vitamin D counseling (on AI); CBC / chemistry only when symptoms or active therapy | — | Routine CBC, chemistry, LFTs, and tumor markers (CEA, CA 15-3, CA 27.29) NOT recommended for asymptomatic stage I-III survivors |
| Imaging | — | Echocardiogram (LVEF) every 3 months on trastuzumab | Echocardiogram every 6 months for 2 years after trastuzumab completion | Mammography of intact / ipsilateral breast | DEXA every 2 years (on AI; on tamoxifen + GnRH; chemo-induced premature menopause) | Breast MRI annually only if ACS high-risk criteria (BRCA1/2, prior chest radiation age 10–30, lifetime risk ≥20%); routine surveillance CT / bone scan / PET NOT recommended in asymptomatic stage I-III survivors |
| Physical exam | Lymphedema assessment + risk-reduction counseling; peripheral neuropathy / AI arthralgia / musculoskeletal review | — | Cancer-related H&P every 3–6 months years 1–3 | Cancer-related H&P every 6–12 months years 4–5, then annually; annual gynecologic assessment (tamoxifen — evaluate AUB promptly, no routine TVUS / biopsy) | — | VTE / DVT symptom inquiry every visit on tamoxifen |
| Functional / surveys | Distress / depression / anxiety screen (PHQ-9, GAD-7, or NCCN Distress Thermometer); fatigue assessment; cognitive concerns ("chemobrain"); sexual / vaginal symptoms; vasomotor symptoms | — | — | Healthy lifestyle counseling (≥150 min/wk activity, weight, alcohol ≤1 drink/day, smoking cessation); age- and risk-appropriate second-primary screening (CRC, cervical, lung) per USPSTF | — | Cardiac rehabilitation post anthracycline / trastuzumab cardiotoxicity per ASCO |
For older women with stage I-III breast cancer in survivorship — the dominant CCW Medicare phenotype — primary-care surveillance is a structured, low-tech, symptom-driven model. ASCO/ACS (Runowicz 2016) and ASCO Follow-Up (Khatcheressian 2013), still the operative US framework and reinforced by NCCN Breast Cancer v5.2025, call for a detailed cancer-related history and physical exam every 3–6 months for the first 3 years, every 6–12 months years 4–5, then annually, plus annual mammography (ipsilateral breast after lumpectomy / radiation; contralateral only after mastectomy).124 Breast MRI is reserved for women meeting ACS high-risk criteria. Routine CBC, chemistries, LFTs, tumor markers, chest imaging, CT, bone scan, and PET are explicitly NOT recommended in asymptomatic survivors. Endocrine therapy adds three monitoring streams: on tamoxifen — annual gynecologic exam with prompt workup of any abnormal vaginal bleeding (no routine TVUS / biopsy) and VTE vigilance;6 on aromatase inhibitor — baseline DEXA and repeat every 2 years, calcium / vitamin D, lipid and cardiovascular risk monitoring, and assessment for AI arthralgia;1 on trastuzumab — baseline echocardiogram, q3-month LVEF during therapy, and q6-month for 2 years after (ASCO 2017 cardio-oncology).3 At every visit, clinicians should screen for lymphedema, fatigue, vasomotor symptoms, sexual dysfunction, depression / distress, cognitive concerns, and peripheral neuropathy; counsel on ≥150 min/wk activity, weight, alcohol ≤1 drink/day, smoking cessation; and confirm age-appropriate second-cancer screening per USPSTF.1
Runowicz CD et al. American Cancer Society / American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(1):43-73. See bibliography.md → ascoacs-bca-2016. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Khatcheressian JL et al. Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2013;31(7):961-965. See bibliography.md → asco-bca-followup-2013. ↩↩↩↩↩
Armenian SH et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: ASCO Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. See bibliography.md → asco-cardio-2017. ↩↩
NCCN. Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025. See bibliography.md → nccn-bca-2025. ↩↩↩↩↩↩↩
USPSTF. Breast Cancer Screening: Recommendation Statement. 2024. See bibliography.md → uspstf-bca-2024. ↩↩
ACOG. Committee Opinion No. 601: Tamoxifen and Uterine Cancer. 2014 (reaffirmed). See bibliography.md → acog-tam-601. ↩↩↩
ICD-10: J45.x (asthma — mild intermittent / persistent / severe; with / without exacerbation) CCW prevalence (2022 Medicare FFS): 7.4% — rank 20 of 30 Category: Respiratory Primary associations consulted: GINA, NAEPP / NHLBI, ATS, AAAAI / ACAAI, CDC
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | — | — | FeNO (diagnostic uncertainty, monitoring response in allergic asthma — NAEPP conditional); blood eosinophil count (severe asthma biologic assessment; ≥3 measurements if below threshold); total / specific IgE (omalizumab candidacy; SCIT candidacy); pre-biologic phenotyping panel |
| Imaging | — | — | — | — | — | Chest x-ray or CT only for atypical features / suspected complication |
| Physical exam | Inhaler technique check (with patient's own device) | — | — | Spirometry (FEV1 / FVC, post-bronchodilator response — at diagnosis, after stabilization, then every 1–2 yr; more often if poor control / declining function / step change) | — | Peak expiratory flow (PEF) daily home monitoring for moderate-severe asthma, poor symptom perceivers, near-fatal asthma history |
| Functional / surveys | ACT or ACQ; reliever / SABA canister use; exacerbation history (OCS bursts, ED visits, hospitalizations, ICU); adherence assessment; trigger / environmental exposure review (tobacco / vaping / occupational / aeroallergens / pollution); smoking / vaping status; asthma action-plan review or update | — | — | Comorbidity surveillance (allergic rhinitis / CRS, GERD, obesity / BMI, OSA screen, VCD / ILO, anxiety / depression); vaccination status (influenza annually, COVID-19, PCV20 or PCV15 + PPSV23, RSV per ACIP, Tdap) | — | Step-up / step-down assessment (GINA Track 1 ICS-formoterol AIR / MART preferred); biologic candidacy assessment when severe / uncontrolled despite optimized step 4–5; pulmonary rehabilitation referral when persistent dyspnea / deconditioning; allergen immunotherapy (SCIT) candidacy in mild-moderate allergic asthma |
US primary-care surveillance of adult asthma follows a structured cadence: initial review 1–3 months after starting or changing controller therapy, then every 3–12 months once stable; within 1 week of any exacerbation; and more frequently for uncontrolled disease or biologic patients.12 At every visit, clinicians administer a validated control instrument (ACT or ACQ), confirm inhaler technique with the patient's own device, review adherence and SABA / reliever canister use, screen for trigger exposures and tobacco / vaping, and update the written asthma action plan.1 Spirometry is obtained at diagnosis, after stabilization, and at least every 1–2 years; home PEF monitoring is added for moderate-severe disease and poor symptom perceivers.21 FeNO is recommended by NAEPP 2020 as an adjunct in diagnostic uncertainty and for monitoring anti-inflammatory therapy in allergic asthma (conditional), but not in isolation; GINA endorses FeNO and blood eosinophils chiefly to phenotype severe asthma and to qualify patients for biologics (BEC ≥150–300 / µL, FeNO ≥20 ppb; total / specific IgE for omalizumab).21 Step-up / step-down is reassessed at every visit using GINA's two-track framework, with Track 1 ICS-formoterol as anti-inflammatory reliever (AIR or MART / SMART) preferred across severity. Annual influenza, COVID-19, and pneumococcal vaccinations are standard. Comorbidities (allergic rhinitis / CRS, GERD, obesity, OSA, VCD / ILO, anxiety / depression) are screened at diagnosis and annually. Severe asthma triggers biologic referral, pulmonary rehabilitation when functionally limited, and SCIT consideration in mild-moderate allergic phenotypes only.2
No routine imaging is recommended for asthma surveillance. Chest x-ray or CT only for atypical features or suspected complication.1
GINA. Global Strategy for Asthma Management and Prevention, 2025 Update. See bibliography.md → gina-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Cloutier MM et al. 2020 Focused Updates to the Asthma Management Guidelines. J Allergy Clin Immunol. 2020;146(6):1217-1270. See bibliography.md → naepp-2020. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
ICD-10: I63.x (cerebral infarction), I61.x (intracerebral hemorrhage), G45.x (TIA), Z86.73 (personal history of TIA / stroke) CCW prevalence (2022 Medicare FFS): 7.0% — rank 21 of 30 Category: Neurologic Primary associations consulted: AHA/ASA, USPSTF, AAN, ACC/AHA, CMS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | INR at least monthly on warfarin (valvular AF / mechanical valve); lipid panel during titration (4–12 wk post-statin start / change) | Lipid panel once stable (q3–12 mo) | HbA1c (DM); CBC + LFTs + Cr / eGFR (DOAC) | — | Diabetes screen (HbA1c or FPG) at baseline; INR weekly during DOAC initiation / change; CBC / LFTs with symptoms |
| Imaging | — | — | — | ECG at baseline post-event | — | Prolonged cardiac rhythm monitoring (≥30 days within 6 mo of event; longer / ILR if cryptogenic with high suspicion); carotid duplex / CTA / MRA (post-CEA / CAS or known symptomatic stenosis); brain CT / MRI for new neurologic symptoms; carotid screening NOT recommended in asymptomatic adults |
| Physical exam | BP, weight / BMI (BP target <130/80) | — | — | — | — | — |
| Functional / surveys | Antithrombotic adherence; tobacco use + cessation counseling; alcohol use; physical-activity counseling (≥10 min moderate aerobic 4×/wk or ≥20 min vigorous 2×/wk); fall-risk assessment | — | — | Depression screen (PHQ-9, at minimum annually); cognitive screen (MoCA; before discharge, again in first year, then periodically); influenza vaccination | — | OSA evaluation with polysomnography; multidisciplinary rehab (PT / OT / speech-language pathology — Medicare Part A inpatient rehab + Part B outpatient); short-course DAPT 21–90 days for minor noncardioembolic ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4) within 24 h; dysphagia / swallow screen pre-PO; NIHSS / mRS at clinical change |
Primary-care surveillance of adults with prior ischemic stroke or TIA centers on five pillars set out in the AHA/ASA 2021 Secondary Prevention Guideline (Kleindorfer et al.) and reinforced by the 2021 AHA Primary Care After Stroke scientific statement (Kernan et al.):12 (1) tight vascular risk-factor control — office BP <130/80 mm Hg at every visit, LDL-C <70 mg/dL for atherosclerotic stroke (lipid panel 4–12 weeks after statin change then every 3–12 months), and HbA1c ≤7% if diabetic; (2) appropriate, adherence-monitored antithrombotic therapy — antiplatelet for noncardioembolic disease (with a 21–90-day DAPT window only for minor stroke / high-risk TIA), and a DOAC (preferred) or warfarin (INR 2–3) for AF or other cardioembolic source, with annual CBC / LFT / renal function on DOACs and at-least-monthly INR on warfarin; (3) occult-AF surveillance with baseline ECG and prolonged (≥30 days) cardiac monitoring after cryptogenic stroke; (4) routine post-stroke screening for depression (PHQ-9), cognitive impairment (MoCA), dysphagia, and fall risk, with PT / OT / speech referrals for residual deficits — services covered by Medicare Part A (inpatient rehab) and Part B (outpatient PT / OT / SLP);5 and (5) lifestyle and ancillary measures — smoking cessation, weight reduction, Mediterranean diet, sodium ≤2.3 g/day, alcohol limitation, OSA evaluation / CPAP, and annual influenza vaccination. The first primary-care visit should occur 1–3 weeks after hospital discharge.2 Red flags prompting urgent re-evaluation include any new focal deficit (FAST / BEFAST symptoms), headache with neurologic change, new arrhythmia, bleeding on antithrombotic, or unexplained syncope / falls.
Kleindorfer DO et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2021;52(7):e364-e467. See bibliography.md → ahaasa-stroke-2021. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Kernan WN et al. Primary Care of Adult Patients After Stroke: AHA/ASA Scientific Statement. Stroke. 2021;52(9):e558-e571. See bibliography.md → aha-pcas-2021. ↩↩↩↩↩
USPSTF. Screening for Asymptomatic Carotid Artery Stenosis: Recommendation Statement. JAMA. 2021;325(5):476-481 (Grade D). See bibliography.md → uspstf-carotid-2021. ↩↩
Chen LY et al. 2024 ACC Expert Consensus Decision Pathway on Practical Approaches for Arrhythmia Monitoring After Stroke. J Am Coll Cardiol. 2025;85(6):657-681. See bibliography.md → acc-arrh-monitor-2024. ↩↩
CMS. Inpatient Rehabilitation Care + Outpatient Therapy Services coverage. See bibliography.md → cms-stroke-rehab. ↩↩
ICD-10: G30.x (Alzheimer's disease); F02.x (dementia in AD) CCW prevalence (2022 Medicare FFS): 2.5% — rank 22 of 30 Category: Neurologic Primary associations consulted: AAN, Alzheimer's Association (DETeCD-ADRD; AUR for lecanemab and donanemab), APA, AGS, USPSTF, CMS
AD shares the dementia surveillance bundle (see Non-Alzheimer's Dementia, #18) and adds an AD-specific layer for anti-amyloid antibody therapy (lecanemab, donanemab) when used.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | Caregiver burden assessment (Zarit) every 6–12 mo | TSH, vitamin B12 at diagnosis | — | APOE genotype before initiating lecanemab / donanemab; amyloid PET or CSF (Aβ42/40, p-tau181/Aβ42) before initiating anti-amyloid; follow-up amyloid PET 12–18 mo after donanemab to consider discontinuation; CBC / CMP for delirium workup |
| Imaging | — | — | — | — | — | Brain MRI (non-contrast preferred; CT if contraindicated) once at diagnosis; baseline MRI ≤12 mo before anti-amyloid initiation; ARIA surveillance MRI before infusions 3, 5, 7, 14 (lecanemab; APOE4 homozygotes may need additional pre-infusion 26 scan); before infusions 2, 3, 4, 7 (and 12 for higher-risk) for donanemab; PRN MRI for any new neurologic symptoms |
| Physical exam | Beers Criteria medication review; antipsychotic appropriateness review (avoid in DLB; in AD use lowest effective dose, taper within 4 mo) | — | — | Fall risk (Timed Up & Go); driving safety (CDR-based); home safety | — | — |
| Functional / surveys | NPI-Q neuropsychiatric symptom screen; vascular risk-factor control; cholinesterase inhibitor / memantine efficacy + tolerability review | — | — | Cognitive testing (MoCA / Mini-Cog / MMSE / SLUMS); ADL / IADL (Katz / Lawton-Brody); FAST or CDR staging; depression screen (GDS-15 or PHQ-9); advance care planning; CMS CPT 99483 Cognitive Assessment & Care Plan (every 180 days); exercise prescription (~twice weekly aerobic) | — | CMS Monoclonal Antibodies Registry submission with each anti-amyloid infusion encounter (NCD 200.3 Coverage with Evidence Development); GUIDE Model enrollment for community-dwelling patients (caregiver navigator, 24/7 helpline, respite up to $2,500/yr) |
AD surveillance layers AD-specific elements on top of the dementia bundle described in Non-Alzheimer's Dementia (#18). The Alzheimer's Association DETeCD-ADRD 2024 guideline and AAN 2001 dementia parameter (reaffirmed 2024) define the diagnostic workup (Tier 1 labs including TSH and B12, structural MRI / CT) and recommend serial cognitive-functional assessment using validated tools (MoCA, MMSE, Mini-Cog), staged with FAST or CDR.12 CMS CPT 99483 operationalizes the care-plan visit in primary care: cognition-focused exam, ADL / IADL, FAST or CDR staging, NPI-Q-type behavioral screen, high-risk medication reconciliation under AGS Beers 2023, home and driving safety, caregiver needs, and advance care planning — billable up to every 180 days.1210 Anti-amyloid antibodies (lecanemab, donanemab) add a separate, intensive surveillance layer: eligibility is restricted to early symptomatic AD (MCI due to AD or mild AD dementia, MMSE 20–30) with amyloid confirmation by PET or CSF; APOE genotyping is performed at baseline to risk-stratify ARIA (~32% ARIA risk for lecanemab in APOE4 homozygotes).56 Baseline MRI within 12 months excludes patients with >4 microbleeds or any superficial siderosis. Surveillance MRI for ARIA is scheduled before infusions 3, 5, 7, and 14 for lecanemab (updated FDA label 2024) and before infusions 2, 3, 4, and 7 (plus 12 for higher-risk) for donanemab.76 Medicare covers therapy only under CMS NCD 200.3 Coverage with Evidence Development, requiring registry participation and submission of cognitive, functional, ARIA, and APOE data.8 Cholinesterase inhibitors and memantine require periodic review for benefit and deprescribing in end-stage disease.
Atri A et al. Alzheimer's Association DETeCD-ADRD Clinical Practice Guideline: Executive Summary for Primary Care. Alzheimer's Dement. 2025. See bibliography.md → alz-detecd-2024. ↩↩↩↩↩↩↩
Knopman DS et al. Practice Parameter: Diagnosis of Dementia. AAN. Neurology. 2001;56:1143-1153. Reaffirmed October 2024. See bibliography.md → aan-dementia-2001. ↩↩↩
Petersen RC et al. Practice Guideline Update Summary: Mild Cognitive Impairment. AAN. Neurology. 2018;90:126-135. See bibliography.md → aan-mci-2018. ↩↩↩↩↩
Iverson DJ et al. Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia. AAN. Neurology. 2010;74:1316-1324. See bibliography.md → aan-driving-2010. ↩
Cummings J et al. Lecanemab: Appropriate Use Recommendations. J Prev Alz Dis. 2023. See bibliography.md → aa-aur-lecanemab. ↩↩↩↩↩
Rabinovici GD et al. Donanemab: Appropriate Use Recommendations. J Prev Alz Dis. 2025. See bibliography.md → aa-aur-donanemab. ↩↩↩↩↩
FDA Drug Safety Communication. Updated MRI Monitoring Schedule for Leqembi (lecanemab). 2024. See bibliography.md → fda-leqembi-2024. ↩↩
CMS. NCD 200.3: Monoclonal Antibodies Directed Against Amyloid for Treatment of AD. See bibliography.md → cms-amyloid-ncd. ↩↩↩↩
Reus VI et al. APA Practice Guideline on Antipsychotics for Agitation or Psychosis in Dementia. Am J Psychiatry. 2016;173(5):543-546. See bibliography.md → apa-dementia-antipsy-2016. ↩↩↩
AGS. 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. See bibliography.md → ags-beers-2023. ↩↩↩↩
USPSTF. Screening for Cognitive Impairment in Older Adults: Recommendation Statement. JAMA. 2020;323(8):757-763. See bibliography.md → uspstf-cog-2020. ↩
CMS. Cognitive Assessment & Care Plan Services (CPT 99483). See bibliography.md → cms-cog-99483. ↩↩↩↩↩↩↩↩↩
CMS Innovation Center. GUIDE Model. 2024-2032. See bibliography.md → cms-guide-2024. ↩↩
Reeve E et al. Deprescribing Cholinesterase Inhibitors and Memantine in Dementia. Med J Aust. 2019. See bibliography.md → reeve-deprescribing-2019. ↩↩
ICD-10: G20 (Parkinson's disease) CCW prevalence (2022 Medicare FFS): 1.9% — rank 23 of 30 Category: Neurologic Primary associations consulted: AAN, Movement Disorder Society (MDS), Parkinson's Foundation, AGS, AAS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | DBS programming review, battery check, neuropsych re-evaluation (DBS patients) | — | — | Genetic testing + counseling via PD GENEration (Parkinson's Foundation; offered to all PD patients regardless of family history) |
| Imaging | — | — | — | — | — | Brain MRI if atypical parkinsonism features; PSG to confirm RBD if treatment considered |
| Physical exam | MDS-UPDRS Parts I–IV (non-motor, motor experiences, motor exam, motor complications); Hoehn & Yahr stage; orthostatic BP (supine + 3-min standing) if symptomatic or on dopaminergic Rx; dopaminergic-regimen review for motor complications (wearing-off, dyskinesia, on-off); avoidance of dopamine-blocking medications (typical / atypical antipsychotics except quetiapine / clozapine / pimavanserin; metoclopramide; prochlorperazine) | — | — | Fall-risk assessment (TUG, pull test); orthostatic BP (annual minimum); dental / oral exam (sialorrhea, dysphagia complication) | — | Driving safety evaluation (CDR / on-road); referral for driving rehab if MoCA <22 or significant motor impairment |
| Functional / surveys | Psychotic symptoms (visual hallucinations, delusions); impulse-control disorder (QUIP-RS — mandatory on any dopamine agonist); fall query; medication-side-effect / adherence review; advance care planning (intensify with cognitive decline or H&Y ≥4); exercise / PT counseling | — | — | Annual PD diagnosis review (re-confirm against MDS clinical diagnostic criteria); cognitive screen (MoCA preferred; MMSE acceptable); psychiatric symptoms (depression, anxiety, apathy — PHQ-9 / GDS); sleep disturbances (RBD via RBDSQ, ESS, insomnia, RLS); autonomic dysfunction (SCOPA-AUT / NMSQ); swallow / dysphagia (EAT-10); speech / hypophonia (refer SLP for LSVT-LOUD); GI motility / constipation; vaccination status (influenza annual, pneumococcal, RSV ≥60, COVID-19, Tdap, zoster ≥50) | — | Multidisciplinary rehab — PT, OT, SLP referral (initiate at diagnosis; reassess annually); pimavanserin (Level B AAN) or quetiapine / clozapine for PD psychosis; impulse-control disorder management → reduce / taper dopamine agonist |
US guideline-aligned surveillance of established Parkinson's Disease centers on a structured visit cadence — every 6 months early, every 3 months with motor fluctuations or new non-motor symptoms, and more frequently in advanced or DBS-managed disease.12 Every visit should include a focused motor exam (MDS-UPDRS Parts III / IV, Hoehn & Yahr) plus structured non-motor screening: falls, psychotic symptoms, and (mandatory on any dopamine agonist) an impulse-control disorder check using QUIP-RS.16 At least annually clinicians should reconfirm the MDS clinical diagnosis, screen cognition (MoCA), mood (PHQ-9), sleep including RBD, autonomic function with a 3-minute orthostatic BP, and dysphagia / speech, and reassess advance care planning, driving safety, and the exercise prescription.15 Medication review at each visit must address motor complications (wearing-off, dyskinesia), screen for dopamine-blocking drugs that worsen PD, and (in adults ≥65) apply the 2023 AGS Beers Criteria.11 Multidisciplinary referral to PT, OT, and SLP is endorsed at diagnosis and reassessed annually. Vaccination should follow ACIP, with prioritization of influenza, pneumococcal, RSV, and COVID-19 given aspiration risk.9 Genetic testing + counseling via PD GENEration is now offered to every person with PD irrespective of family history.10
No routine laboratory monitoring is required for PD surveillance.
AAN. Parkinson Disease Update Quality Measurement Set. 2020 update. See bibliography.md → aan-pd-qm-2021. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Pringsheim T et al. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline. AAN. Neurology. 2021;97(20):942-957. See bibliography.md → aan-pd-dopa-2021. ↩↩↩↩↩↩
Postuma RB et al. MDS Clinical Diagnostic Criteria for Parkinson's Disease. Mov Disord. 2015;30(12):1591-1601. See bibliography.md → mds-criteria-2015. ↩↩↩↩
Goetz CG et al. MDS-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Mov Disord. 2008;23(15):2129-2170. See bibliography.md → mds-updrs-2008. ↩
Bloem BR et al. Delivering Multidisciplinary Rehabilitation Care in Parkinson's Disease: International Consensus Statement. Mov Disord. 2024. See bibliography.md → pf-rehab-2024. ↩↩↩↩↩↩
Debove I et al. Management of Impulse Control and Related Disorders in Parkinson's Disease: Expert Consensus. Mov Disord. 2024. See bibliography.md → mds-icd-2024. ↩↩
Camilleri M et al. Consensus Practice Recommendations for Management of Gastrointestinal Dysfunction in Parkinson Disease. 2024. See bibliography.md → pf-gi-2024. ↩
Gibbons CH et al. Recommendations of a Consensus Panel for the Screening, Diagnosis, and Treatment of Neurogenic Orthostatic Hypotension. J Neurol. 2017;264(8):1567-1582. See bibliography.md → aas-oh-2017. ↩↩↩
Parkinson's Foundation. Hospital Care Recommendations. April 2023. See bibliography.md → pf-hospital-2023. ↩↩↩
Parkinson's Foundation. PD GENEration: National Genetic Testing & Counseling Initiative. 2024. See bibliography.md → pf-genetics-2024. ↩↩↩
AGS. 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. See bibliography.md → ags-beers-2023. ↩↩↩↩↩
ICD-10: C18.x (colon), C19 (rectosigmoid), C20 (rectum) CCW prevalence (2022 Medicare FFS): 1.5% — rank 24 of 30 Category: Cancer Primary associations consulted: NCCN, ASCRS, ASCO/ACS Survivorship, USPSTF, ACG
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | CEA every 3–6 mo × 2 yr (stage II/III; T2 or higher) | CEA every 6 mo through yr 5 (stage II/III); discontinue after 5 yr stable | — | — | CEA NOT routine for stage I; ctDNA emerging (not yet routine) |
| Imaging | — | — | CT chest / abdomen / pelvis every 6–12 mo × 5 yr (stage II/III/IV); MRI pelvis every 6 mo × 3 yr (rectal cancer, particularly watch-and-wait); proctoscopy / flexible sigmoidoscopy q3–6 mo × 2 yr after rectal transanal excision or nonoperative management | CT chest / abd / pelvis annually × 5 yr (stage I-III ACS recommendation); chest CT alternative; PET / CT NOT recommended for routine surveillance | Surveillance colonoscopy at 1 yr post-resection (or 3–6 mo postoperatively if pre-op exam incomplete); repeat at 3 yr if normal; then every 5 yr | — |
| Physical exam | — | H&P every 3–6 mo × 2 yr (stage II/III) | H&P every 6 mo through yr 5 | H&P annually after yr 5 (stage I-III NED); ostomy site assessment if applicable; peripheral neuropathy / CIPN (post-oxaliplatin) | — | — |
| Functional / surveys | — | — | Distress / depression / anxiety screen (NCCN Distress Thermometer, PHQ-9, HADS) | Lifestyle counseling (≥150 min/wk activity, BMI, diet, alcohol ≤1 drink/day, smoking cessation); age-appropriate second-cancer screening per USPSTF; Lynch syndrome surveillance if applicable (annual endometrial biopsy + TVUS starting age 35; upper endoscopy; urinary tract); financial / psychosocial assessment | — | Fatigue screening, sexual function / fertility counseling, ostomy care WOC referral, bowel dysfunction / LARS / proctitis management, CIPN — duloxetine for painful CIPN; survivorship care plan within 1 yr of treatment completion |
For curatively-resected stage II/III colon and rectal cancer survivors — the dominant CCW Medicare CRC cohort — convergent NCCN v4.2025 (colon) / v2025 (rectal), ASCRS 2021, and ASCO / ACS (El-Shami 2015) guidance specifies: history and physical examination every 3–6 months for the first 2 years and every 6 months through year 5, with paired serum CEA on the same cadence; CT chest / abdomen / pelvis every 6–12 months for 5 years (NCCN / ASCRS) or annually × 5 years (ACS), reserved for patients who would be candidates for further intervention; surveillance colonoscopy at 1 year post-resection (or 3–6 months postoperatively if a complete pre-op exam was not feasible), repeated at year 3 and then every 5 years if normal; rectal-specific pelvic MRI every 6 months for up to 3 years (especially watch-and-wait or high-risk) and proctoscopy / flexible sigmoidoscopy at 3–6 month intervals after transanal excision or nonoperative management.123 Beyond tumor surveillance, guidelines require structured screening for distress / depression, oxaliplatin-induced peripheral neuropathy (offer duloxetine for painful CIPN), bowel dysfunction / LARS, ostomy care, sexual function, fertility (reproductive-age), lifestyle counseling, cardiovascular risk, age-appropriate second-cancer screening (and Lynch-specific surveillance if applicable), and a documented survivorship care plan transitioning to coordinated primary-care follow-up.3 Stage I disease is monitored less intensively (colonoscopy plus H&P; routine CT and CEA generally not required); stage IV NED after metastasectomy is monitored more intensively (CEA and CT every 3–6 months × 2 years).1
NCCN. Clinical Practice Guidelines in Oncology: Colon Cancer v4.2025 and Rectal Cancer v2025. See bibliography.md → nccn-crc-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Vogel JD et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2022;65(2):148-177. See bibliography.md → ascrs-crc-2021. ↩↩↩↩↩↩↩↩↩↩
El-Shami K et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines (ASCO endorsement). CA Cancer J Clin. 2015;65(6):428-455. See bibliography.md → ascoacs-crc-2015. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
ICD-10: I21.x (acute MI), I22.x (subsequent MI), Z86.711 (personal history of MI) CCW prevalence (2022 Medicare FFS): 1.3% — rank 25 of 30 Category: Cardiovascular Primary associations consulted: AHA/ACC/SCAI/NAEMSP, 2023 CCD Guideline, CMS
Post-MI surveillance overlaps substantially with Ischemic Heart Disease (#7). This monograph focuses on the acute / subacute and first-year phase. After ~12 months post-event, surveillance generally follows the 2023 CCD framework.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Lipid panel 4–8 weeks after statin initiation / change, then every 3–12 months | — | Lipid panel (stable, target LDL <70; <55 very high risk); HbA1c (if DM); influenza + COVID-19 + RSV vaccination review | — | Troponin / ECG with new or changing symptoms (NOT routine surveillance — Class 3 No Benefit for routine) |
| Imaging | — | — | — | — | — | Echocardiogram for LVEF reassessment ~40 days post-MI (and ≥90 days post-revasc) if initial LVEF reduced, to guide ICD decision; reassess with clinical change |
| Physical exam | BP, weight / BMI, physical activity | — | — | — | — | — |
| Functional / surveys | Adherence — aspirin 81 mg + P2Y12 inhibitor (ticagrelor / prasugrel preferred over clopidogrel) through DAPT window; β-blocker (≥1 year minimum; indefinitely if LVEF <50% / angina / arrhythmia / HTN); ACEi / ARB / ARNI (LVEF ≤40% or HTN / DM / CKD); SGLT2i (LVEF ≤40% or T2DM); MRA (LVEF ≤40% + HF / DM); GLP-1 RA if T2DM or BMI ≥27; low-dose colchicine 0.5 mg daily (selected residual inflammatory risk, Class 2b); tobacco cessation; Mediterranean / DASH / low-sodium diet | Clinical follow-up visit every 4–6 months in first year, then ≥annually | — | PHQ-2 / PHQ-9 depression screen; alcohol; physical-activity counseling (150 min/wk moderate or 75 min/wk vigorous + resistance 2×/wk) | — | Cardiac rehabilitation referral pre-discharge (CMS NCD 20.10: 36 sessions over 12 weeks within 12 mo post-AMI; extendable to 72 if comorbid event); ICD evaluation ≥40 days post-MI AND ≥90 days post-revascularization if LVEF ≤35% NYHA II–III (or ≤30% any class) after GDMT optimization |
Post-MI ambulatory surveillance is most intensive in the first 30–90 days, when guidelines emphasize cardiac rehab enrollment (CMS NCD 20.10 covers 36 sessions in 12 weeks within the 12 months post-AMI), rapid GDMT titration to target doses within 3 months, and a fasting lipid panel 4–8 weeks after statin initiation.126 After this stabilization phase, visits typically drop to every 4–6 months in year one, then at least annually if stable. DAPT (aspirin 81 mg + ticagrelor or prasugrel preferred) is continued ≥12 months post-ACS (Class I); ticagrelor monotherapy after 1+ month is a Class 2a option in high bleeding risk.1 After 12 months, aspirin monotherapy is the chronic standard. High-intensity statin is lifelong with LDL-C target <70 mg/dL (Class I) and <55 mg/dL for very-high-risk patients, escalating to ezetimibe, PCSK9 inhibitors, inclisiran, or bempedoic acid as needed.13 β-blockers are recommended for at least 1 year post-MI and indefinitely if LVEF ≤50%, angina, arrhythmia, or HTN coexist (the 2023 CCD guideline made indefinite continuation without these indications Class 2b).2 ACEi / ARB and SGLT2 inhibitors are Class I for post-MI patients with LVEF ≤40%; MRA is added when HF symptoms or diabetes coexist.24 ICD evaluation occurs ≥40 days post-MI (and ≥90 days post-revascularization) only after full GDMT optimization, with echo to reconfirm LVEF ≤35% (NYHA II–III) or ≤30%.1 BP target is <130/80, A1c per ADA, and every visit should address PHQ-2 depression screening, tobacco cessation, alcohol use, weight, physical activity, Mediterranean-style diet, and annual influenza / COVID / RSV vaccinations.
Rao SV et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025. See bibliography.md → accaha-acs-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
Virani SS et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148:e9-e119. See bibliography.md → accaha-ccd-2023. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026. See bibliography.md → accaha-dyslip-2026. ↩↩↩↩
Maddox TM et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF. J Am Coll Cardiol. 2024. See bibliography.md → acc-hfref-ecdp-2024. ↩↩
ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR. 2025 Appropriate Use Criteria for ICD, CRT, and Pacing. J Am Coll Cardiol. 2025. See bibliography.md → acc-icd-auc-2025. ↩
CMS. National Coverage Determination 20.10: Cardiac Rehabilitation Programs. See bibliography.md → cms-cr-ncd. ↩↩
ICD-10: J12-J18 (bacterial / viral / unspecified pneumonia) CCW prevalence (2022 Medicare FFS): 1.3% — rank 26 of 30 Category: Respiratory Primary associations consulted: IDSA / ATS, CDC ACIP, USPSTF
CCW classifies pneumonia as a chronic-condition rubric reflecting recurrent / persistent disease burden in older adults. This monograph covers post-CAP surveillance, recurrent pneumonia workup, and vaccination-based prevention.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | Pneumococcal vaccination status (PCV20 or PCV21 single dose, or PCV15 followed ≥1 yr later by PPSV23 — adults ≥50 / risk-based 19-49); influenza vaccine annually; RSV ≥75 (or 50–74 with risk); COVID-19 per CDC; Tdap | — | Blood cultures × 2 (severe CAP / MRSA / Pseudomonas risk / hospitalization with parenteral antibiotics in past 90 days); sputum Gram stain + culture (same severe CAP indications); urinary S. pneumoniae and Legionella antigens (severe CAP); procalcitonin (NOT to initiate antibiotics; conditional for de-escalation / duration); recurrent-pneumonia workup labs (serum immunoglobulins IgG/IgA/IgM + IgG subclasses, HIV test) |
| Imaging | — | — | — | — | — | Follow-up chest x-ray at 6–8 wk in selected patients (persistent symptoms, smokers ≥50 eligible for lung-cancer screening, recurrent same-lobe pneumonia — CT preferred); chest CT for structural lung disease / bronchiectasis / malignancy / sequestration; routine repeat CXR NOT recommended in patients improving within 5–7 days |
| Physical exam | — | — | — | BMI / nutritional status; COPD optimization | — | Pulse oximetry / SpO2 (acute); arterial blood gas if SpO2 ≤92% or for LTOT qualification; swallow evaluation for aspiration; delirium screening during hospitalization |
| Functional / surveys | Smoking-cessation counseling | — | — | Vaccination status review (comprehensive); cognitive change post-pneumonia surveillance in older adults | — | Post-CAP clinical resolution visit 1–2 weeks after diagnosis; recurrent-pneumonia (≥2 episodes/yr or 3 lifetime) workup — immunodeficiency assessment, structural lung disease, aspiration evaluation |
Per the 2019 IDSA / ATS CAP guideline (Metlay et al.), management of adults diagnosed with community-acquired pneumonia centers on a clinical resolution follow-up visit at approximately 1–2 weeks; routine follow-up chest x-ray is NOT recommended for patients improving by 5–7 days, but selective imaging at 6–8 weeks is appropriate in patients with persistent symptoms, smokers eligible for lung cancer screening, or recurrent same-lobe pneumonia.1 Routine sputum cultures, blood cultures, and pneumococcal / Legionella urinary antigens are reserved for severe CAP or specific risk groups, not outpatient CAP. Procalcitonin is NOT recommended to initiate antibiotics but may guide de-escalation / duration. Prevention rests on CDC / ACIP vaccinations: a single dose of PCV15, PCV20, or PCV21 for all PCV-naïve adults ≥50 years (lowered from ≥65 in October 2024), with PPSV23 ≥1 year later only if PCV15 was chosen; risk-based pneumococcal vaccination applies to adults 19–49 with chronic heart / lung / liver / kidney disease, diabetes, immunocompromise, alcoholism, or smoking.2 Annual influenza vaccination is universal (HD / adjuvanted / recombinant preferred ≥65 years). RSV vaccination is a single non-annual dose for all adults ≥75 and for adults 50–74 with risk conditions (expanded April 2025).4 COVID-19 vaccination for 2025–26 moved to shared clinical decision-making. Smoking cessation counseling is integral. Recurrent pneumonia (≥2 episodes/year) warrants workup for immunodeficiency (immunoglobulin levels, HIV), structural lung disease (chest CT, bronchoscopy), and aspiration. Older adults hospitalized for CAP have substantial post-discharge cognitive / functional decline risk and warrant delirium screening and post-discharge cognitive surveillance.
Metlay JP et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia: An Official ATS / IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(7):e45-e67. See bibliography.md → idsa-cap-2019. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
CDC / ACIP. Pneumococcal Vaccine Recommendations. Updated 2024 (≥50 years threshold effective Oct 23, 2024). See bibliography.md → cdc-pneumo-2024. ↩↩↩
CDC / ACIP. Prevention and Control of Seasonal Influenza with Vaccines: 2025-26 Recommendations. MMWR 2025;74(32). See bibliography.md → cdc-flu-2025. ↩
CDC. RSV Vaccine Guidance for Adults. Updated April 2025. See bibliography.md → cdc-rsv-2025. ↩↩
CDC / ACIP. 2025-2026 COVID-19 Vaccination Guidance (shared clinical decision-making). See bibliography.md → cdc-covid-2025. ↩↩
Girard TD et al. Long-Term Cognitive Impairment after Hospitalization for Community-Acquired Pneumonia. J Gen Intern Med. 2018;33(6):929-935. See bibliography.md → girard-cap-cog-2018. ↩↩
ICD-10: C34.x (malignant neoplasm of bronchus and lung) CCW prevalence (2022 Medicare FFS): 1.3% — rank 27 of 30 Category: Cancer Primary associations consulted: NCCN, USPSTF, CMS, ASCO, ATS, ACCP
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | irAE labs (TSH, LFTs, glucose, cortisol) prior to each immunotherapy infusion; response assessment imaging every 6–12 wk on active systemic therapy | — | Broad molecular profiling at diagnosis of advanced / metastatic nonsquamous NSCLC (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK, ERBB2 / HER2, NRG1, PD-L1 IHC); repeat at progression | — | Circulating biomarkers (ctDNA, CEA) NOT recommended for routine surveillance |
| Imaging | — | — | Chest CT with contrast every 6 mo × 2–3 yr (stage I-II NSCLC); every 6 mo × 3 yr (stage III NSCLC); ASCO 2019 every 6 mo × 2 yr; chest CT every 2–6 mo × 1 yr then every 3–6 mo × 2–3 yr (SCLC); brain MRI every 3–4 mo × 1 yr then every 6 mo × 2 yr (limited-stage SCLC) | Annual low-dose non-contrast chest CT after initial 2–3 yr surveillance window; annual LDCT lung-cancer screening for high-risk adults 50–80 yr with 20+ pack-year history (USPSTF Grade B; CMS NCD 210.14 ages 50–77, requires one-time shared decision-making visit / G0296) | — | Brain MRI NOT recommended routinely in stage I-III NSCLC (use only when symptomatic); PET / CT NOT recommended for routine surveillance |
| Physical exam | Dyspnea and cough assessment | — | H&P + chest CT every 6 mo × 2–3 yr | H&P annually after initial window | — | Dental / oral evaluation prior to thoracic RT; periodic on bone-modifying agents (zoledronic acid, denosumab for bone metastases) |
| Functional / surveys | Smoking-cessation counseling + pharmacotherapy (combined behavioral + pharmacotherapy); distress screening (NCCN Distress Thermometer) | — | — | Cancer-related fatigue screening; depression / anxiety (PHQ-9, GAD-7); chemotherapy-induced peripheral neuropathy (post-platinum / taxane); dietary counseling / weight management; age-appropriate other-cancer screening per USPSTF; vaccinations per ACIP | — | Pulmonary rehabilitation pre-op (prehab) and post-op (6–12 wk program) for lung resection; symptomatic survivors with dyspnea / deconditioning |
Post-curative NSCLC surveillance per NCCN v.2025 consists of H&P plus contrast-enhanced chest CT every 6 months for the first 2–3 years (longer interval for stage III), transitioning to annual low-dose non-contrast chest CT thereafter for life; ASCO 2019 endorses the same 6-mo × 2 yr then annual schedule.15 PET / CT and routine circulating biomarkers are explicitly NOT recommended for asymptomatic surveillance, and routine brain MRI is not recommended in stage I-III NSCLC (reserve for symptoms). Limited-stage SCLC requires intensified surveillance: chest CT every 2–6 months and brain MRI every 3–4 months in year 1, every 6 months in year 2 (NCCN SCLC v.2.2026).2 Metastatic NSCLC on active therapy requires response imaging every 6–12 weeks plus comprehensive molecular profiling at diagnosis (EGFR, ALK, ROS1, BRAF, KRAS G12C, MET ex14, RET, NTRK, HER2, NRG1, PD-L1) to guide targeted therapy and IO selection.1 Population screening with annual LDCT applies to adults 50–80 with ≥20 pack-years currently smoking or quit ≤15 years (USPSTF 2021 Grade B; CMS NCD 210.14, 2022, requires a one-time shared decision-making visit / G0296).34 Survivorship care addresses smoking cessation at every visit (combined behavioral + pharmacotherapy), pulmonary rehabilitation pre / post-resection, surveillance for platinum-induced peripheral neuropathy, screening for depression, fatigue, distress, dyspnea, dietary counseling, and age-appropriate other-cancer screening.6
NCCN. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 2025. See bibliography.md → nccn-nsclc-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩
NCCN. Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer, Version 2.2026. See bibliography.md → nccn-sclc-2026. ↩↩↩↩
USPSTF. Screening for Lung Cancer: Recommendation Statement. JAMA. 2021;325(10):962-970. See bibliography.md → uspstf-lung-2021. ↩↩↩
CMS. National Coverage Determination 210.14: Lung Cancer Screening with Low Dose Computed Tomography. Effective February 10, 2022. See bibliography.md → cms-lung-ncd-2022. ↩↩↩↩↩
Schneider BJ et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol. 2020;38(7):753-766. See bibliography.md → asco-lung-2019. ↩↩↩↩↩↩↩↩↩
NCCN. Clinical Practice Guidelines in Oncology: Survivorship, Version 2.2025. See bibliography.md → nccn-surv-2025. ↩↩↩↩↩↩↩↩↩↩
NCCN. Clinical Practice Guidelines in Oncology: Smoking Cessation, Version 2.2025. See bibliography.md → nccn-smoking-2025. ↩
NCCN. Management of Immunotherapy-Related Toxicities, Version 2025. See bibliography.md → nccn-irae-2025. ↩
Rochester CL et al. Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: ATS Clinical Practice Guideline. Am J Respir Crit Care Med. 2023;208(4):e7-e26. See bibliography.md → ats-pr-2023. ↩
ICD-10: S72.x (hip fracture), S32.x (pelvic fracture), M84.x (pathologic fracture), Z87.81 (personal history of pathologic fracture) CCW prevalence (2022 Medicare FFS): 1.2% — rank 28 of 30 Category: Musculoskeletal Primary associations consulted: AAOS, ASBMR, BHOF, AGS, ACS GSV, CDC STEADI, CMS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | — | — | 25-OH vitamin D (post-repletion); calcium intake assessment | — | Baseline secondary-causes labs (Ca, 25-OH vit D, PTH, alk phos, Cr / eGFR, Mg, TSH, CBC, 24-hr urine Ca) before anti-resorptive initiation; serum Ca prior to IV zoledronate / denosumab dose; CTX / P1NP for adherence + response 3–6 mo after therapy start |
| Imaging | — | — | — | DEXA every 1–2 yr on therapy (AACE) or 1–3 yr (Endo Society) until stable | — | Baseline DEXA at index hospitalization or 1st outpatient visit if not previously osteoporotic; targeted radiographs only when clinically indicated (pain, function decline, suspected nonunion / hardware failure); vertebral fracture assessment (VFA) per BHOF triggers |
| Physical exam | Pain assessment; mobility / PT / OT progress | Multidisciplinary rehabilitation (PT, OT, SLP as indicated) — daily IRF (≥3 hr/day); SNF therapy ≥5 d/wk; outpatient PT ongoing | — | Standing height measurement; Timed Up and Go (TUG) screening; fall-risk reassessment via CDC STEADI Screen-Assess-Intervene | — | Comprehensive geriatric assessment (cognition, function, nutrition, goals of care, polypharmacy); CAM delirium screen daily / per shift through post-op hospital stay (age ≥75); surgical-site / hardware imaging only when clinically indicated |
| Functional / surveys | Pain control; medication review for falls / orthostasis / sedation (AGS Beers Criteria) | — | Denosumab continuity check (no gap >7 mo) | FRAX 10-yr fracture-risk recalculation; depression screen (PHQ-2 / PHQ-9) at 1, 3, 6, 12 mo PCP visits; secondary fracture risk score | — | FLS (Fracture Liaison Service) / Own the Bone enrollment during index hospitalization; anti-resorptive initiation (oral bisphosphonate first-line; IV zoledronic acid annual; denosumab q6 mo) within months of fracture; VTE prophylaxis (LMWH / DOAC / aspirin) minimum 10–14 days, extendable 28–35 days post-op |
Post-hip / pelvic fracture surveillance in adults ≥65 follows a phased trajectory anchored by interdisciplinary co-management.12 Acute inpatient and IRF care (Medicare Part A, no 3-day rule for IRF) includes ACS-GSV-aligned daily delirium screening, multimodal pain control, 10–35-day VTE prophylaxis, and ≥3 hr/day therapy.1012 Post-discharge SNF coverage (up to 100 days / benefit period; cost share after day 20 in 2026) or home-health continues PT / OT, with primary-care visits typically at 1, 3, 6, and 12 months.12 At those visits, clinicians repeat the CDC STEADI fall-risk screen (TUG <12 s target), apply the 2023 AGS Beers Criteria to deprescribe sedatives, anticholinergics, orthostasis-inducing agents, and other fall-risk drugs, and assess vitamin D and calcium adequacy (1,000–1,200 mg Ca / day; vitamin D supplementation in adults ≥75).711 If not previously diagnosed, DEXA is obtained (USPSTF 2025 grade B in women ≥65 and high-risk postmenopausal women).4 The ASBMR Secondary Fracture Prevention coalition, BHOF, and AOA's Own the Bone program direct prompt anti-resorptive initiation (IV zoledronic acid annually — strongest mortality / fracture-reduction evidence from HORIZON-RFT; oral alendronate or risedronate first-line; denosumab when bisphosphonates contraindicated), ideally coordinated through a Fracture Liaison Service.28 Ongoing surveillance includes depression screening, cognition monitoring, FRAX recalculation, and serial BMD on therapy.
AAOS. Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline. Dec 2021. See bibliography.md → aaos-hip-2021. ↩↩↩↩↩↩
Conley RB et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. JBMR. 2020. See bibliography.md → asbmr-secondary-2019. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩
LeBoff MS et al. The Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2022;33(10):2049-2102. See bibliography.md → bhof-2022. ↩↩↩↩↩↩↩↩
USPSTF. Screening for Osteoporosis to Prevent Fractures: Recommendation Statement. JAMA. 2025;333(6):498-508. See bibliography.md → uspstf-osteo-2025. ↩↩
Eastell R et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019. See bibliography.md → endo-osteo-2019. ↩
Camacho PM et al. AACE / ACE Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. See bibliography.md → aace-osteo-2020. ↩↩↩↩
CDC. STEADI — Older Adult Fall Prevention. Updated 2025. See bibliography.md → cdc-steadi. ↩↩↩↩
Lyles KW et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture (HORIZON-RFT). N Engl J Med. 2007. See bibliography.md → horizon-rft-2007. ↩↩↩↩
Demay MB et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. JCEM. 2024. See bibliography.md → endo-vitd-2024. ↩↩
American College of Surgeons. Geriatric Surgery Verification Program Standards. See bibliography.md → acs-gsv. ↩↩↩↩
AGS. 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. See bibliography.md → ags-beers-2023. ↩↩↩
CMS. Inpatient Rehabilitation Care + Skilled Nursing Facility Care coverage. See bibliography.md → cms-rehab-coverage. ↩↩
ICD-10: C54.x (malignant neoplasm of corpus uteri) CCW prevalence (2022 Medicare FFS): 1.1% (females only) — rank 29 of 30 Category: Cancer (females only) Primary associations consulted: NCCN, SGO, ACOG, USPSTF, ACS
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Serum CA-125 only if elevated at baseline / diagnosis (otherwise NOT routine) | — | — | — | Universal MMR IHC (± MLH1 methylation reflex) ± MSI on tumor at diagnosis for Lynch syndrome screening; germline genetic counseling / testing if MMR-deficient (not MLH1 methylation) or strong family history; irAE labs (TSH, LFTs, glucose, cortisol) baseline + prior to each cycle of checkpoint inhibitor (pembrolizumab / dostarlimab) |
| Imaging | — | H&P + pelvic exam every 3–6 mo × 2–3 yr (stage III/IV or serous / clear cell every 3 mo) | H&P + pelvic exam every 6 mo through yr 5 (after initial high-frequency window); CT chest / abdomen / pelvis every 6 mo × 3 yr (stage III-IV, serous / clear cell, carcinosarcoma) | — | — | Vaginal / pelvic MRI or CT as clinically indicated for symptoms or abnormal exam; response imaging CT chest / abd / pelvis every 2–3 cycles (≈ every 9–12 wk) during active systemic therapy for metastatic / recurrent disease |
| Physical exam | — | H&P with speculum + bimanual pelvic exam every 3–6 mo first 2–3 yr | H&P every 6 mo through yr 5 | H&P annually after yr 5; lymphedema surveillance + education (post-pelvic lymphadenectomy / pelvic RT) | — | — |
| Functional / surveys | Patient education on recurrence symptoms (vaginal bleeding, pelvic / abdominal pain, cough, weight loss, leg swelling); distress / depression / anxiety screening (NCCN Distress Thermometer) | — | — | Lifestyle counseling (weight management, exercise, healthy diet, smoking cessation — endometrial cancer is metabolically driven); cardiovascular risk management (BP, lipids, diabetes screening); vasomotor symptom management (non-hormonal preferred; HT case-by-case); sexual health / vaginal health (moisturizers, dilators after vaginal brachytherapy); bone health (DXA per osteoporosis guidelines, especially if premenopausal at oophorectomy); age-appropriate other-cancer screening (breast, cervical per ACS / USPSTF, colorectal — accelerated to age 20–25 q1–2 yr if Lynch+) | — | Vaginal cuff cytology / Pap NOT recommended routinely (discontinued in current NCCN — symptom-driven evaluation only) |
US post-treatment surveillance for endometrial cancer is driven primarily by NCCN Uterine Neoplasms v3.2025 and the 2025 SGO clinical practice statement, which are aligned.12 H&P with speculum and bimanual pelvic exam is performed every 3–6 months for the first 2–3 years and then every 6–12 months through year 5 (annually thereafter), with frequency stratified by risk: stage IA grade 1–2 disease at the lower end (every 6 months) and stage III-IV or serous / clear cell histology every 3 months for 2–3 years. Routine vaginal cuff cytology has been discontinued — it detects <1% of recurrences, is cost-ineffective, and both NCCN and SGO (Choosing Wisely) explicitly recommend against it; evaluation is symptom- and exam-driven. Routine surveillance CT is NOT recommended for low-risk stage I disease but IS recommended every 6 months for years 1–3 in stage III-IV, serous / clear cell, or carcinosarcoma. Serum CA-125 is reserved for patients with elevated baseline levels (TOTEM trial showed no benefit in routine use).1 Universal Lynch syndrome tumor screening with MMR IHC ± MSI is recommended at diagnosis for all newly diagnosed endometrial cancers regardless of age (NCCN, SGO, ACOG).134 Survivorship care emphasizes lifestyle counseling (weight, exercise, diabetes, lipids), vasomotor and sexual health management, lymphedema surveillance, bone health after surgical menopause, distress screening, and age-appropriate other-cancer screening. USPSTF has issued no recommendation for endometrial cancer screening in asymptomatic average-risk women. Patients on active systemic therapy for metastatic / recurrent disease receive response imaging every 9–12 weeks and irAE labs with checkpoint inhibitor regimens.
NCCN. Clinical Practice Guidelines in Oncology — Uterine Neoplasms, Version 3.2025. See bibliography.md → nccn-uterine-2025. ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
SGO. Updates to Post-Treatment Surveillance After Curative-Intent Treatment for Patients With Gynecologic Cancers: A Society of Gynecologic Oncology Clinical Practice Statement. Gynecol Oncol. 2025. See bibliography.md → sgo-uterine-2025. ↩↩↩↩↩↩↩↩↩
SGO. Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer. See bibliography.md → sgo-lynch. ↩↩↩
ACOG. Practice Bulletin No. 147: Lynch Syndrome. See bibliography.md → acog-lynch-2014. ↩↩
ICD-10: C67.x (bladder), C64-C66 (kidney / renal pelvis / ureter) CCW prevalence (2022 Medicare FFS): 0.9% — rank 30 of 30 Category: Cancer Primary associations consulted: AUA / SUO, AUA / ASCO / SUO, NCCN, ASCO, USPSTF
CCW classifies bladder cancer and renal cell carcinoma together as "urologic cancer" (excluding prostate, which is condition #17). Both have distinct surveillance schedules and are addressed separately.
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | Urine cytology every 3–6 mo × 2 yr (intermediate / high-risk NMIBC); BCG response assessment cytology at 3 + 6 mo post-induction (high-risk on BCG); annual B12 starting 2–3 yr post-diversion (ileal conduit / neobladder); BMP / acid-base every 3–6 mo early postop, then annually (post-cystectomy diversions) | Renal function (Cr / eGFR) + upper-tract imaging every 6 mo through yr 3 (post-cystectomy) | Renal function + upper-tract imaging annually after yr 3 (post-cystectomy); B12 annually | — | Urinary biomarkers should NOT replace cystoscopy; selectively in surveillance |
| Imaging | — | Cystoscopy every 3–4 mo × 2 yr (high-risk NMIBC); every 3–6 mo × 2 yr (intermediate-risk); CT chest + CT / MRI abd / pelvis every 6–12 mo × 2–3 yr (post-cystectomy for MIBC) | Cystoscopy every 6 mo yrs 3–4 (high / intermediate-risk NMIBC); CT chest + abd / pelvis annually after yr 3 (post-cystectomy) | Cystoscopy annually after yr 4–5 (NMIBC); upper-tract imaging (CT / MR urography) every 1–2 yr (intermediate / high-risk NMIBC); cystoscopy first at 3–4 mo, then 6–9 mo, then annually (low-risk NMIBC) | Shared decision-making to discontinue cystoscopy after 5 yr recurrence-free (low-risk NMIBC) | Urethral wash cytology periodically if urethra retained (especially with prostatic urethral involvement); routine bladder cancer screening NOT recommended in asymptomatic adults (USPSTF I-statement) |
| Physical exam | — | — | — | — | — | Sexual / urinary function and ostomy / neobladder care |
| Functional / surveys | — | — | — | — | — | — |
For NMIBC, the AUA / SUO 2024 Amendment recommends cystoscopy + cytology every 3–4 months × 2 years, every 6 months for years 3–4, then annually for high-risk disease, with upper-tract imaging (CT / MR urography) every 1–2 years; intermediate-risk uses every 3–6 month cystoscopy tapering to annual; low-risk requires cystoscopy at 3–4 months, 6–9 months, then annually, with no routine cytology or upper-tract imaging.1 Post-cystectomy MIBC patients (AUA / ASCO / SUO 2024) require chest + abd / pelvis CT or MRI every 6–12 months × 2–3 years then annually, plus lifelong metabolic monitoring (annual B12 for ileal-segment diversions, BMP for acid-base) and renal function / upper-tract surveillance.2
| Type | Every visit | Quarterly | Every 6 months | Annually | Every 2–3 years | As indicated |
|---|---|---|---|---|---|---|
| Labs | — | BMP / eGFR / CBC / LDH every 6 mo × 3 yr (stage II-III high-risk); response imaging on systemic therapy every 6–16 wk; irAE labs on ICI / TKI per regimen | — | BMP / Cr / eGFR / CBC / LDH annually (stage I); renal function annually (small renal mass on AS) | — | TSH / LFTs / BMP / CBC per ICI / TKI toxicity schedule; bone scan / brain MRI only if symptomatic (bone pain, ↑ alk phos, neurologic symptoms) |
| Imaging | — | Abdominal CT or MRI + chest CT every 3–6 mo × 3 yr (high-risk post-resection stage II-III); response imaging every 6–16 wk (stage IV on systemic therapy); abdominal imaging every 3–6 mo yr 1 (small renal mass on AS) | — | Abdominal imaging (CT / MRI; ultrasound acceptable after baseline) annually × 3 yr or longer (stage I post-resection); chest imaging (CXR or chest CT) annually × at least 5 yr; chest CT preferred annually × 5 yr (stage II-III high-risk after initial intensive window); abdominal imaging annually after yr 1 (small renal mass on AS) | — | — |
| Physical exam | — | H&P every 3–6 mo × 3 yr (stage II-III post-resection) | — | H&P annually (stage I); H&P annually to yr 5 (stage II-III); H&P + labs annually (stage I post-resection) | — | — |
| Functional / surveys | — | — | — | — | — | Renal-function preservation counseling (NSAID avoidance, contrast safety); active surveillance candidacy reassessment for small renal mass (growth <5 mm/yr; size <3–4 cm) |
For RCC (AUA Renal Mass 2021; NCCN 2024–2025), stage I post-resection requires baseline imaging at 3–12 months then annually × 3+ years with annual chest imaging × 5 years; stage II-III requires every 3–6 month chest + abdominal CT × 3 years tapering to annual through year 5; small renal masses on active surveillance need imaging every 3–6 months in year 1 then every 6–12 months.34 Stage IV on systemic therapy requires response imaging every 6–16 weeks per regimen plus immunotherapy / TKI toxicity surveillance (TSH, LFTs, BMP, CBC).5
US guidelines support intensive, risk-stratified surveillance for both major urologic cancers. NMIBC surveillance is anchored in cystoscopy + cytology every 3–4 months for years 1–2 in high-risk disease, tapering to annual after year 5; low-risk NMIBC is more permissive, with cytology and upper-tract imaging not routinely required. Post-cystectomy MIBC patients require chest + abd / pelvis CT or MRI every 6–12 months × 2–3 years then annually, plus annual B12 for ileal-segment diversions and renal-function / upper-tract surveillance. RCC post-resection cadence varies by stage (annual stage I; every 3–6 months × 3 years for stage II-III high-risk). Active surveillance for small renal mass requires baseline-to-frequent imaging early then annually. USPSTF gives bladder cancer screening in asymptomatic adults an "I" (insufficient evidence) statement.6
AUA / SUO. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA / SUO Guideline (2016; Amended 2020, 2024). J Urol. 2024. See bibliography.md → aua-nmibc-2024. ↩↩↩
AUA / ASCO / SUO. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA / ASCO / SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024. See bibliography.md → aua-mibc-2024. ↩↩
AUA. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline, Parts I and II. 2021. See bibliography.md → aua-renal-2021. ↩↩
NCCN. Clinical Practice Guidelines in Oncology: Kidney Cancer. 2024-2025. See bibliography.md → nccn-kidney-2025. ↩↩
ASCO. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. 2022. See bibliography.md → asco-rcc-2022. ↩↩
USPSTF. Bladder Cancer in Adults: Screening (Final Recommendation, "I" statement). 2011. See bibliography.md → uspstf-bladder-2011. ↩
Authoritative associations and source documents cited across the 30 condition monographs. Listed by abbreviation. Each entry includes the full name of the issuing body, the cited document(s), and a hyperlink to the canonical source page.
CMS — Centers for Medicare & Medicaid Services. https://www.cms.gov USPSTF — U.S. Preventive Services Task Force. Recommendation index: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics CDC — Centers for Disease Control and Prevention. https://www.cdc.gov NIH — National Institutes of Health. https://www.nih.gov NHLBI — National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov NIDDK — National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov NCI — National Cancer Institute. https://www.cancer.gov NEI — National Eye Institute. https://www.nei.nih.gov NIAMS — National Institute of Arthritis and Musculoskeletal and Skin Diseases. https://www.niams.nih.gov SAMHSA — Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov VA/DoD — Department of Veterans Affairs / Department of Defense Clinical Practice Guidelines. https://www.healthquality.va.gov/
AHA — American Heart Association. https://www.heart.org ACC — American College of Cardiology. https://www.acc.org ADA — American Diabetes Association. Standards of Care (annual). https://diabetesjournals.org/care/issue ASN — American Society of Nephrology. https://www.asn-online.org KDIGO — Kidney Disease: Improving Global Outcomes. https://kdigo.org ATA — American Thyroid Association. https://www.thyroid.org ATS — American Thoracic Society. https://www.thoracic.org AAN — American Academy of Neurology. https://www.aan.com ACR — American College of Rheumatology. https://www.rheumatology.org NLA — National Lipid Association. https://www.lipid.org AACE — American Association of Clinical Endocrinology. https://www.aace.com AAO — American Academy of Ophthalmology. https://www.aao.org AUA — American Urological Association. https://www.auanet.org APA — American Psychiatric Association. https://www.psychiatry.org NCCN — National Comprehensive Cancer Network. https://www.nccn.org AGS — American Geriatrics Society. https://www.americangeriatrics.org AAFP — American Academy of Family Physicians. https://www.aafp.org EULAR — European Alliance of Associations for Rheumatology. https://www.eular.org ASH — American Society of Hematology. https://www.hematology.org AGA — American Gastroenterological Association. https://gastro.org
NKF — National Kidney Foundation. https://www.kidney.org ALA — American Lung Association. https://www.lung.org Alz — Alzheimer's Association. https://www.alz.org BHOF — Bone Health and Osteoporosis Foundation. https://www.bonehealthandosteoporosis.org Parkinson's Foundation. https://www.parkinson.org Arthritis Foundation. https://www.arthritis.org Urology Care Foundation. https://www.urologyhealth.org
Each entry below uses the citation key referenced in the condition files (e.g., [^aha-htn-2017]).
(See also Non-Alzheimer's Dementia for shared sources: alz-detecd-2024, aan-dementia-2001, aan-mci-2018, aan-driving-2010, apa-dementia-antipsy-2016, ags-beers-2023, uspstf-cog-2020, cms-cog-99483, cms-guide-2024.)
(See also Ischemic Heart Disease for accaha-ccd-2023, cms-cr-ncd.)
(See also Pneumonia for ats-pr-2023; COPD for uspstf-lung-2021.)
(See also Osteoporosis for uspstf-osteo-2025, aace-osteo-2020, endo-osteo-2019, bhof-2022; Non-Alzheimer's Dementia for ags-beers-2023.)